This is a summary list of all resource providers at Harvard University . The list includes links to more detailed information, which may also be found using the eagle-i search app.
The mission of the Advanced Fetal Care Center (AFCC) is to provide the finest diagnosis and care for a mother carrying a baby with a congenital anomaly. For these families, our center offers entry to a continuum of care and support that extends throughout childhood--from prenatal diagnosis and counseling, through treatment and long-term follow-up. On rare occasions, our team will recommend and perform intervention during fetal life. Our physicians, who represent all pediatric subspecialty areas, work with a wide range of babies with anomalies. Together, they have developed ground-breaking procedures in fetal medicine and surgery.
The Advanced Microscopy Core of Joslin ‘s Diabetes Research Center facilitates the ready availability of sophisticated morphological techniques by providing electron microscopic services, a confocal microscope facility, a laser capture microdissection facility, as well as preparation of frozen or paraffin sections from tissues provided by investigators Additionally we provide protocols, analysis and interpretation.
Since the core is subsidized by the NIH funded DRC, members of the Joslin DRC have priority and a discounted fee-for-service. Use by outsiders will be considered if there is time available, with NIH grant holders given preference.
The Joslin Animal Physiology Core provides technically advanced physiological evaluation of rodents. The core has non-invasive devices for the study of metabolism under conditions of exercise, diabetes, obesity, and unique diets. In addition, the core has 2D and 3D in vivo optical imaging for the measurement of fluorescence, bioluminescence and microCT. The facility at Joslin enables external users to access the core via an associated quarantine room for the importation of mice. Core personnel offer their expertise in designing and executing a variety of physiological assessments. For any inquiries about Core services, please contact Core personnel.
The facility provides services and resources for investigators looking to accomplish animal research objectives. This includes housing mice and rats, purchasing animals, training researchers regarding proper animal care and use, and monitoring the safety of all personnel with laboratory animal contact in conjunction with Dana-Farber’s Environmental Health and Safety and Occupational Health Services.
Dana-Farber has established an Institutional Care and Use Committee (IACUC) to oversee the Institute’s animal program, facilities, and projects involving the use of animals. The IACUC serves as the approval body for all protocols involving animal research, and assists faculty, students and staff in upholding Dana-Farber’s commitment to providing the finest care and most humane utilization of laboratory animals.
In addition to basic husbandry services, the ARF staff provides technical and veterinary services, mouse breeding management and mouse irradiation.
Occupying 265 acres, the Arboretum’s living collection of trees, shrubs, and woody vines is recognized as one of the most comprehensive and best documented of its kind in the world. The living collection is supported by comprehensive curatorial documentation, herbaria containing more than 1.3 million specimens, extensive library and archival holdings, and a 43,000-square-foot state-of-the-art research center. These facilities and holdings, along with 75 full-time staff, provide the basis for research and education by Harvard faculty and students, Arboretum scholars, and visiting scientists from around the world. ", "The Arnold Arboretum of Harvard University is the oldest public arboretum in North America and one of the world’s leading centers for the study of plant biodiversity. Its mission is to integratively examine plant diversity—from genomic, developmental, organismic, evolutionary, and ecosystem perspectives—in order to foster greater understanding and appreciation of plant life in its full complexity.
The Weld Hill Growth Facilities consist of 12 individually controlled greenhouses and several types of Conviron growth chambers for precise control of growing conditions.
Microscopists at Weld Hill will find a range of tools from the simple hand lens to the confocal microscope for 3-D reconstructions.
The molecular lab at Weld Hill is well equipped for modern molecular studies, from RNA expression studies to phylogenetic analyses.
The Assay Development and Screening Facility (ADSF) provides consultation and implementation of high-throughput and high-content screening assays on a fee-for-service model. The core has specialized equipment to support image-based and live cell assay development. The ADSF also partners with the Human Neuron Differentiation Service to create and conduct phenotypic screening using patient derived iPSC lines differentiated into specific neuronal cell types to model human CNS disorders.
Our Core is designed to teach and/or perform for users the following assays.
If you would like the core to perform these assays for you, contact Dr Peroni.
Consultation and assistance on writing animal protocols regarding services offered by the Core
The BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center provides all of the tools of modern functional genomics and proteomics combined with in depth bioinformatics and systems biology analysis, for academic and corporate clients alike. Equipped with State-of-the-Art technologies for high throughput transcriptional profiling, genotyping, protein quantitation, protein profiling and identification, real-time PCR and robotics and various systems biology tools. The BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology center is a core proteomics facility for the Dana-Farber/Harvard Cancer Center.
• In-house developed workflows and algorithms for analysis of next-generation sequencing data including RNA-Seq, ChIP-Seq, Epigenetics-Seq and DNA seq
• Comprehensive workflow for analysis of Microbiome sequencing data
• Integrated systems biology analysis of transcriptome, miRNA, epigenome, metabolomics and proteomics data
• Coming soon on in-house development pipelines: MALDI Tissue imaging and targeted quantitative proteomics.
The core offers Comprehensive Laboratory Animal Monitoring System (CLAMS) studies to noninvasively measure a variety of calorimetric and metabolic data in mice. The calorimetric data recorded by the system includes oxygen consumption and carbon dioxide production values, from which both heat values and respiratory exchange ratios (RER) can be calculated.
Biostatistics support is available to investigators in the Brigham and Women's and Harvard Medical research community for statistical consulting on issues such as study design and data analysis for manuscripts and grant applications. Resources are limited, so planning ahead is essential. The Biostatistics Consulting Service is part of the Biostatistics Core of the BWH Center for Clinical Investigation (CCI).
The mission of the BWH Medicinal Chemistry Core is to serve the Partners HealthCare and non-Partners research communities providing expertise and knowhow to help investigators engage Medicinal Chemistry in their basic or translational studies in an efficient and cost-effective manner.
The BWH Research Imaging Core (BRIC) provides a comprehensive research imaging service to meet the needs of investigators and research subjects using imaging facilities at Brigham and Women’s Hospital (BWH). The BRIC has been developed in close collaboration with the Brigham CTSA Imaging Team of the Harvard Catalyst Translational Imaging Program. A unique feature of BRIC is the complete anonymity of research subjects. Research image scheduling, image acquisition and image storage are all kept completely separate from BWH clinical Radiology systems. The BRIC provides the administrative infrastructure, customer service architecture and institutional support to promote investigative applications of imaging technologies.
The BRI includes nine disease-focused research centers and five resource-and technology-based programs that develop and support collaborative research initiatives. This infrastructure allows our diverse community of clinicians and scientists to communicate more effectively, providing numerous opportunities for them to collaborate on research aimed at curing, treating and preventing human diseases and conditions.
"The Specimen Bank provides materials to investigators with IRB-approved protocols. Staff are available to assist with selection of samples appropriate for downstream applications, development of processing protocols or preparation of derivatives from clinical materials.
IT Staff are also available to assist researchers with creation of queries for prospective sample collection or queries to select samples from specific cohorts.
Our goal is to drive quality research in an efficient and cost-effective manner. Each year we provide tens of thousands of samples to area researchers."
Getting started: Partners investigators and study staff may request a Crimson user account to help manage studies and collected materials.
The BWH-BRI Antibody Core Facility provides high quality, purified monoclonal antibodies to the BWH research community. Because the antibodies are made in-house and require no shipping, they are available at a cost substantially lower than that of commercial vendors. Antibodies are of standardized quality and are available in two convenient aliquots: 500ugs and 10mgs. The Core maintains an inventory of commonly used antibodies, which allows orders to be filled quickly.
Biorepository responsible for collection, storage and distribution of specimens from longitudinal cohorts at the Channing Division of Network Medicine.
Part of the Babraham Institute.
Our goal is to advance research efforts in the life sciences that cannot readily be accomplished in the traditional academic laboratory because of a need for expensive instrumentation or automation, scientific or organizational infrastructure, or multidisciplinary expertise.
To promote cutting-edge research and to foster scientific collaborations, we make our extensive laboratory and computational resources available to scientists at Harvard. Our technical staff provide expertise and hands-on training in protocols and the use of instrumentation for a nominal fee. Researchers can sign up to use the instrumentation through an on-line scheduling system and conduct their experiments independently.
The Laboratory for Magnetic Brain Stimulation provides a cutting edge methodology for assessing the function of the cerebral cortex and motor systems. The method of repetitive cortical magnetic stimulation was pioneered by Dr. Pascual-Leone, the Director of the Laboratory, and is currently finding uses in a variety of clinical situations, ranging from depression and movement disorders to neurorehabilitation.
Clinical work includes studies of central motor conduction time, cortical excitability, noninvasive determination of hemispheric dominance for language, and noninvasive cortical mapping. In addition, our clinical program offers noninvasive brain stimulation for treatment of neuropsychiatric disorders such as depression and schizophrenia, epilepsy, dystonia, Parkinson's disease, chronic pain, and the neurorehabilitation of hand function and language after stroke.
In the first few years of life, humans tremendously expand their behavioral repertoire and gain the ability to engage in complex, learned, and reward-driven actions. Similarly, within a few weeks after birth mice can perform sophisticated spatial navigation, forage independently for food, and engage in reward reinforcement learning. Our laboratory seeks to uncover the mechanisms of synapse and circuit plasticity that permit new behaviors to be learned and refined. We are interested in the developmental changes that occur after birth that make learning possible as well as in the circuit changes that are triggered by the process of learning. Lastly, we examine how perturbations of these processes contribute to human neuropsychiatric disorders such as Tuberous Sclerosis Complex and Parkinson’s Disease. Take a video tour of the lab and building (actually a music video produced for Chairlift filmed, in part, in our lab)
The mission of Bioinformatics and Systems Biology core is to provide expertise and infrastructure in designing, analyses and simulation of high-throughput OMICS data to answer underlying biological questions. The core supports analysis of data from many next-generation sequencing assays, including transcriptional quantification (RNA-Seq), protein-nucleic acid interactions (ChIP-Seq), global methylation, genotyping or variant analysis through genome sequencing. To support cutting edge research, a special emphasis was made on implementing/developing systems biology frameworks and models for integrative analysis of genomic, epigenomics proteomic, metabolomic, imaging and clinical data to identify key molecules driving pathophysiology. The core has unique service to predict the Antigenic regions (T-epitope, B –epitopes) from the gene and protein sequences to predict potential subunit vaccine candidates.
The Bioinformatics and Biostatistics Core at Joslin Diabetes Center offers support for data-driven projects related to basic, clinical and translational research, with a particular emphasis on diabetes. The core aims to ensure that researchers take advantage of the most modern and robust methods available in the field of Bioinformatics and Biostatistics
The Biological Analysis Service facility provides and/or facilitate access to digital imaging and biological analysis services in and out of Harvard campus. We aim to foster new research opportunity for HSPH investigator through providing initial support for pilot studies. Check out Bioanalysis "Mini-Pilot Funding" for description of the funding mechanism and an application form to request funds.
* Biomedical Imaging
* Flow Cytometry
* Electron Microscopy
* Proteomics Facility
* Molecular Analysis Facility
"The mission of the Biomedical Research Informatics Core (BRIC) is to utilize the expertise of BIDMC 'informaticians' with backgrounds in medicine, biology, engineering, biostatistics, and computer science to facilitate research at our institution by (a) providing a high level of service and experience in informatics that is difficult for individual laboratories to achieve and maintain, (b) developing the infrastructure required to address common informatics needs of all researchers, and (c) identifying areas in which there can be closer collaboration among life scientists and quantitative scientists."
View our portfolio for examples of BRIC projects. To arrange for a free consultation, please contact Griffin Weber. If you choose to use BRIC services, hourly fees vary depending on the types of services needed. You will be given an estimate of the number of hours before any work begins.
Our mission is to provide investigators with access to technologies and services that will help them speed along their research programs while conserving both time and money by not having to conduct certain experiments within their own labs. We strive to provide high quality data and a rapid turn-around time for all samples. In addition, we provide a wide variety of the most popular reagents and supplies for immediate pick up from our facility.
The Biospecimen Repository provides long-term storage of clinical and research material in -80° C and liquid nitrogen freezers located at Dana Farber's Harbor Campus. Transportation of samples to and from Harbor Campus is provided by the facility for a small fee. Competitive prices are available on per box or per freezer basis in both segregated or non-segregated environments.
The BDAC provides collaborative support in the design, execution and analysis of clinical trials and epidemiology studies conducted at the Boston OAIC. Additionally, the BDAC provides mentoring and collaborative opportunities for students and junior faculty in quantitative aspects of the study of physical function and impairments in aging. The BDAC is equipped to provide critical services on a consulting basis (e.g. in an advisory capacity in critical review of study data collection procedures) and more formally (e.g. in conducting simulation studies and power calculation). Furthermore, the BDAC provides support for ongoing projects by providing critical review and expertise in evaluating study conduct, or more extensive, pre-specified contributions to trial objectives. Support services for study completion are also available in providing guidance and assistance in statistical analyses, as well as co-authorship of abstracts and manuscripts describing study results.
"The Biostatistics Core facility is a shared resource supporting consultation on biostatistics and epidemiology throughout the Dana-Farber/Harvard Cancer Center (DF/HCC). The mission of the core is to ensure that experimental designs, study monitoring and data analyses take advantage of robust, efficient methods that reflect 'best practices' in biostatistics and epidemiology; to support NIH-funded peer reviewed grants that do not contain salary support for statisticians; and to enable pilot and small scale studies to become part of successful applications for peer-reviewed funding."
These services are available to Dana-Farber / Harvard Cancer Center members only. The Biostatistics Core is located across several of the member institutions of the DF/HCC. To contact the Core, please email or call the statistician associated with your disease site.
The Blais Proteomics Center develops and applies state-of-the-art proteomics, informatics, and related technologies for direct interrogation of protein expression, modification, and function in response to biological perturbation in cell-based models of human cancer and primary tissues. The Blais Proteomics Center serves as a valuable resource to support individual research labs at the Dana-Farber and throughout the surrounding research community. As a key component of Dana-Farber’s Strategic Plan for Research, Blais Proteomics actively participates with other Dana-Farber Strategic Research Centers in large-scale studies, designed to leverage disparate capabilities in pursuit of novel, in-depth, and otherwise unattainable insights into human biology and disease. Consistent with our role as a world-class, center of excellence in proteomics science, members of the Blais Proteomics center contribute to the teaching mission at Harvard Medical School and participate in outreach activities designed to introduce and train young scientists and others who may not otherwise have access to these advanced technologies.
To advance interdisciplinary health sciences research and innovation by providing high quality bone density and body composition measures to investigators at Brigham and Women’s Hospital (BWH), Partners HealthCare and the broader, medical and research community.
The BWH Bone Density and Body Composition Research Core uses the latest technology to provide high quality, reproducible measures of bone mineral density (BMD) and body composition by dual energy x-ray absorptiometry (DXA). Dr. Meryl S. LeBoff is the Director of the Bone Density and Body Composition Research Core and has extensive experience in assessing bone density and body composition. She is the Chief of the Calcium and Bone Section and Director of the Skeletal Health and Osteoporosis Center and Bone Density Unit in the Endocrinology, Diabetes and Hypertension Division at BWH. She is a trustee for the National Osteoporosis Foundation and served on the 2013 Expert Panel for the International Society for Clinical Densitometry’s (ISCD) Position Statement on Bone Density and Body Composition Measures. She and the staff at the Bone Density and Body Composition Research Core have been performing clinical research scans for more than 25 years and are committed to maintaining the highest standards of quality control.
We are conveniently located at 221 Longwood Avenue, which is accessible by the Partners Masco M2 and Ruggles buses, MBTA buses and the T. Valet parking is also available.
The Boston Area Diabetes Endocrinology Research Center (BADERC) is a consortium of laboratory-based and clinical investigators whose efforts are directed toward addressing many of the major research questions bearing on the etiology, pathogenesis, treatment and cure of type 1 and type 2 diabetes, and their associated microvascular and atherosclerotic complications. The center Director (Joseph Avruch and Associates Directors (Joel F. Habener and Brian Seed) are highly productive senior investigators of international stature in signal transduction, gene expression, molecular biology and immunology, topics central to advances in diabetes research. The participating scientists are based at a large number of Boston-area research institutions, primarily the major Harvard Medical School-affiliated teaching hospitals (the Massachusetts General Hospital, the Brigham and Women’s Hospital, the Beth Israel-Deaconess Medical Center) and the Boston University Medical Center, as well as several at the Harvard School of Arts and Sciences and other Harvard-affiliated research institutions (School of Public Health, the Dana-Farber Cancer center, the Scheppens Eye Research Institute), the New England Medical Center and the Massachusetts Institute of Technology. These investigators are working at the cutting edge of fields most relevant to defining the pathogenesis and optimal treatment of type 1 and type 2 diabetes: The molecular and genetic basis of insulin action and insulin resistance; the biology of the vascular system and beta cell; the immunologic basis and optimal therapies for autoimmunity and transplant rejection; the development of new methods for glycemic monitoring and control.
Boston Biomedical Research Institute is an independent not for profit institution dedicated to basic biomedical research to promote the understanding, treatment and prevention of specific human diseases, and to the training of research scientists.
Children's is home to the world's largest research enterprise based at a pediatric hospital. More than 1,100 scientists, including nine members of the National Academy of Sciences, 11 on-staff members of the Institute of Medicine and 9 members of the Howard Hughes Medical Institute, comprise our research community. Current initiatives have attracted a record $225 million in annual funding, including more federal funding than any other pediatric facility.
Viral Core’s goal is to provide scientists with access to cutting-edge viral vector technologies in an effective, high-quality and cost-efficient fashion. Viral Core also provides consultation to investigators in selecting, designing and using viral vectors.
Boston Children's at Waltham is a state-of-the-art outpatient facility providing the same high-quality pediatric and adolescent specialty care you'll find at all our locations. Since 2005, Boston Children's at Waltham has been treating everything from broken bones to more complex conditions—making it a cornerstone of our Community of Care.
Boston Medical Center (BMC) is a 508-bed academic medical center located in Boston’s historic South End. The hospital is the primary teaching affiliate for Boston University School of Medicine.
BMC provides a full range of pediatric and adult care services, from primary to family medicine to advanced specialty care. It is the largest and busiest provider of trauma and emergency services in New England. Emphasizing community-based care, BMC is committed to providing consistently excellent and accessible health services to all—and is the largest safety-net hospital in New England.
Dr. David Breault's research has exploited the fact the mouse telomerase (mTert) is a biomarker for embryonic and tissue stem cells. He has developed a streamlined technique for isolating and characterizing adult stem cells from a variety of tissues using genetically engineered reporter mice.
The Eli and Edythe L. Broad Institute of Harvard and MIT is founded on two core beliefs:
1. This generation has a historic opportunity and responsibility to transform medicine by using systematic approaches in the biological sciences to dramatically accelerate the understanding and treatment of disease.
2. To fulfill this mission, we need new kinds of research institutions, with a deeply collaborative spirit across disciplines and organizations, and having the capacity to tackle ambitious challenges.
The Broad Institute is essentially an “experiment” in a new way of doing science, empowering this generation of researchers to:
* Act nimbly. Encouraging creativity often means moving quickly, and taking risks on new approaches and structures that often defy conventional wisdom.
* Work boldly. Meeting the biomedical challenges of this generation requires the capacity to mount projects at any scale — from a single individual to teams of hundreds of scientists.
* Share openly. Seizing scientific opportunities requires creating methods, tools and massive data sets — and making them available to the entire scientific community to rapidly accelerate biomedical advancement.
* Reach globally. Biomedicine should address the medical challenges of the entire world, not just advanced economies, and include scientists in developing countries as equal partners whose knowledge and experience are critical to driving progress.
For over twenty years, we've been pushing the boundaries of genomics by producing high quality data in a scalable environment. Broad Institute Genomic Services represents a new model for collaboration, offering the global community unprecedented access to capabilities.
Inquiry Form: http://genomics.broadinstitute.org/tell-us-about-your-project
The Bulyk Lab investigates transcriptional regulation. We are particularly interested in transcriptional enhancers and the interactions between sequence-specific transcription factors and their DNA binding sites. For these studies, we develop genomic, proteomic, and computational technologies and approaches and apply them to a wide variety of biological organisms including the yeast S. cerevisiae, the fruit fly D. melanogaster, mouse and human.
The CCIB DNA Core, founded in 1995, is a well-established major research core laboratory within the Center for Computational and Integrative Biology of Massachusetts General Hospital Boston. The Facility provides a wide range of state-of-the-art services and specialized expertise in genomics, molecular biology, and laboratory automation to the greater Partners research community.
As the need for high-throughput research efforts is growing, the demand for laboratory automation solutions increases. To meet this demand, the Laboratory Automation unit has been designed as a flexible entity within the CCIB DNA Core to extend the benefits of laboratory automation to a diverse user group by providing standard and custom medium- to high-throughput sample processing services for various molecular biology and genomics applications. One of the many unique capabilities of the group is its proficiency in special automation process design and implementation.
The CCIB DNA Core, founded in 1995, is a well-established major research core laboratory within the Center for Computational and Integrative Biology of Massachusetts General Hospital Boston. The Facility provides a wide range of state-of-the-art services and specialized expertise in genomics, molecular biology, and laboratory automation to the greater Partners research community.
The CCIB DNA Core has the expertise to perform specialized services for investigators who are considering genotyping, DNA profiling, and mutation detection techniques for their research. Our experienced team - staff members from both the Sequencing group and the Laboratory Automation group - are providing fast, reliable, and cost-effective solutions for genetic analysis applications such as DNA Fragment Analysis (Microsatellite, MLPA) and Mouse Genotyping.
The CCIB DNA Core, founded in 1995, is a well-established major research core laboratory within the Center for Computational and Integrative Biology of Massachusetts General Hospital Boston. The Facility provides a wide range of state-of-the-art services and specialized expertise in genomics, molecular biology, and laboratory automation to the greater Partners research community.
The DNA Sequencing division of the CCIB DNA Core functions both as a small-scale sequencing facility and a high-throughput center for large-scale sequencing projects. It offers solid experience in conventional Sanger DNA sequencing and DNA Fragment Analysis (Microsatellite/MLPA), and reliably provides high-quality services with rapid turnaround time and competitive pricing. In support of the ever-growing research community’s needs, the Sequencing group is now also offering cost-effective high-throughput approaches for specific Next-Generation Sequencing applications such as Complete Plasmid Sequencing and CRISPR Amplicon Sequencing.
The CCIB DNA Core, founded in 1995, is a well-established major research core laboratory within the Center for Computational and Integrative Biology of Massachusetts General Hospital Boston. The Facility provides a wide range of state-of-the-art services and specialized expertise in genomics, molecular biology, and laboratory automation to the to the greater Partners research community.
The Oligonucleotide Synthesis division of the CCIB DNA Core provides investigators with custom oligonucleotides for use in a wide range of genetics applications including DNA sequencing, PCR, cDNA synthesis, hybridization, and in vitro mutagenesis. In continuous operation since 1996, our division is committed to supplying the greater Partners research community as well as non-Partners research organizations with high-quality products at low cost and with rapid turnaround time.
This resource provides to MGH investigators a local source of breeding pairs of the 22 chromosome substitution strains (CSS)* of mice and access to basic phenotyping equipment for mapping of simple or complex traits, to promote the use of genetic mouse-based strategies in basic and clinical research.
The CSS Resource comprises 22 mouse lines, each homozygous for a single A/J chromosome (Chr 1-19, X or Y and mitochondria) on a genetic background that is otherwise C57BL/J that were generated by Dr. Joseph Nadeau (Case Western Reserve University) and his colleagues. The CSS mice are available from The Jackson Laboratories. However, to save time and money, the MGH CSS Resource maintains CSS breeding colonies that are housed in the Simches-8 barrier facility, adjacent to a procedure room that will have equipment for basic standardized phenotyping, including behavioral and metabolic measurements.
The Clinical Genetic Research Facility (CGRF) offers clinical investigators a convenient, modern research-dedicated facility for outpatient studies involving genetics. Our outpatient exam rooms and phlebotomy rooms are fully equipped and offer investigators an experienced medical assistant to facilitate the visit.
Since the CGRF’s primary mission is to support and promote genetic clinical research, the facility’s investigators performing genetic studies supported by non-commercial sponsors are given priority. The CGRF also considers genetic studies sponsored by industry, as well as studies without a genetic component, on a space-available basis.
This facility provides processing of cell lines, human blood and tissue samples for DNA, plasma and buffy coat storage and for initiation of lymphoblast and fibroblast cell lines in furtherance of the CHGR mission to promote the use of genetic strategies in basic and clinical research.
This resource provides custom genotyping (microsatellite, SNP, other) in human and mouse, mutation detection/DNA sequencing, dosage analysis and related services to further the CHGR mission of promoting the use of genetic strategies in basic and clinical research.
Center for Nanoscale Systems facility dealing with "SEM, TEM, ESEM, sample prep etc."
The Center for Nanoscale Systems' Nanofabrication Facility (CNS-NF), offers resource and staff support for fabricating and characterizing nanoscale devices and structures.
The facility currently operates the 10,000 sq.ft. LISE Cleanroom with leading-edge equipment capable of electron-beam and optical lithography, physical and chemical vapor deposition, dry and wet processing, metrology, and device characterization.
Center for Nanoscale Systems facility dealing with "FIB, XPS, AFM, Optical Microscopy and Spectroscopy, Biomaterials, Soft Lithography, Microfluidics, Nano Particles, Chemical Nanotechnology, etc."
The Center for Personalized Cancer Therapy (CPCT) Genomics Core was established in 2015 to enable UMass Boston investigators and academic and industry collaborators to carry out basic and translational genomics research. The Core leverages cutting-edge technologies and next-generation sequencing capabilities for research and clinical applications. We help investigators and clinicians analyze samples, identify genetic variants contributing to disease risk, and reveal complex mechanisms involved in human disease.
The Core offers cost-effective massively parallel sequencing with the Illumina HiSeq 2500 (v4, 1TB enabled) and Illumina MiSeq platforms, and next-generation sequencing library preparation from RNA and DNA and nucleic acid quality assessments. Our Nanostring nCounter Analysis System allows highly sensitive, multiplexed gene expression analysis.
The CPCT is a collaborative venture between the University of Massachusetts Boston and the Dana-Farber/Harvard Cancer Center (DF/HCC).
Cytometry and cell sorting core at the Center for Virology and Vaccine Research. The facility has a BD FACSAria II housed in a sterile biosafety cabinet in a BSL2+ facility, allowing sorting of unfixed, live cells into a variety of tubes and plates. Equipment, consultation, dedicated operator, and data analysis available to outside researchers.
To schedule an appointment please contact one of our flow core personnel.
The Cancer Pharmacology Core provides DF/HCC investigators with the necessary expertise and resources to design and undertake pharmacokinetic studies in the context of phase I and phase II clinical trials, and preclinical investigations. The core has the ability to implement and validate previously developed analytical methods to quantify drugs and their metabolites in biological fluids as well as the capability to modify or develop entirely new assays when warranted. The core also offers comprehensive analysis of pharmacokinetic data as an additional service, including the estimation of pharmacokinetic parameters and identifying their relationship to pathophysiological variables and pharmacodynamic effects.
The goal of Cardiac Physiology Core is to provide expertise in evaluation of cardiac pathology for non-cardiovascular and cardiovascular researchers who are not equipped for such analysis." The core provides "non-invasive and invasive evaluation of cardiac physiology that may be difficult or time-consuming for those investigators without proper expertise, experience and equipments.
The Carpenter Lab is based at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, USA. Our research group develops advanced methods and software tools to quantify and mine the rich information present in cellular images to yield biological discoveries. Our laboratory is best known for our open source software packages CellProfiler and CellProfiler Analyst.
The (Connell and O'Reilly Families) Cell Manipulation Core Facility (CMCF), at Dana-Farber Cancer Institute (DFCI) was created in 1996 to be a manufacturing facility for production of safe and effective novel cellular component therapies, that meet regulatory guidelines for clinical use and enable cellular therapies to be translated from the bench to bedside. The goal of this facility is to assist DF/HCC investigators and sponsors in developing new cell-based therapies for cancer, gene therapy products for genetic diseases, and adoptive immunotherapy products. Many of these cellular products are manufactured in the context of clinical research studies designed to evaluate the toxicity and efficacy of novel treatments.
The CMCF facility, located in the Jimmy fund building, is dedicated to the production of clinical-grade cellular therapy products for patients who participate in clinical trials conducted by DF/HCC investigators. All procedures are performed in environmentally-controlled conditions according to current Good Manufacturing Practices (cGMP) established for cell and tissue processing. The third floor accommodates all of the production clean room areas while space on the ground floor is devoted to the storage of cellular products, tissues, and blood and tumor samples in liquid nitrogen and mechanical freezers. In addition, the Pasquarello Tissue Repository, located on the 6th floor, collects and stores patient samples solely for research use.
The CMCF is available to both clinical and laboratory investigators at all DF/HCC institutions and will provide services to patients at all DF/HCC affiliated hospitals. The staff of the CMCF are committed to working with DF/HCC investigators at all levels of clinical trial development and execution. In addition to manufacture of clinical grade cellular therapy products, CMCF services include pre-clinical development of manufacturing procedures, facilitation of DF/HCC and FDA review, data management, in-process and release testing of products, quality control monitoring, coordination of internal and external audits, and generation of reports for publication. The CMCF has been accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), and is licensed by CLIA to perform high-complexity testing. The CMCF supports the Cancer Vaccine Center at DFCI, the Center for Human Cell Therapy at Boston Children’s Hospital and is also a member of the Joint Program in Transfusion Medicine.
Leadership and Staff
Director: Jerome Ritz, MD
Assistant Medical Director / Clinical Instructor: Sarah Nikiforow MD, PhD
Administrative Director: Olive Sturtevant, BA, MT (ASCP) , SBB, SLS, MHP
Technical Director - Stem Cell Therapies Lab: Darlys Schott, BS, MT (ASCP), SBB
Technical Director - Novel Cellular Therapies Lab: Hélène Negre, PharmD, PhD
Quality Assurance Manager: Mary Ann Kelley, BS, MT (ASCP)
Associate Business Director: Elaine Zive BS, MBA
Systems Manager: Philip Brzezinski, BS, MBA
Systems Manager: Josh Geary, BA
Supervisor, Novel Cellular Therapies Lab: Heather Daley, BS
Supervisor, Stem Cell Therapies Lab: Karl Stasko, BS, MPH
Supervisor, Quality Control Lab: Renee Manduke, BS
Supervisor, Pasquarello Tissue Lab: Doreen Hearsey, BS
Program Administrator: Gerry MacDonald
Certificates/Registration of Accreditation
The Joint Commission Accreditation Letter
FACT Accreditation Certificate
CMS & CLIA Accreditation Certificate
The Stem Cell Core Facility has been part of the IDDRC center for more than 30 years fostering collaboration and innovation among IDDRC investigators and members of the academic research community. It was used to develop chromosome sorting for human chromosome specific recombinant libraries and these techniques were utilized by others to generate large scale libraries for the early genome project. The facility was the first to develop cell sorting of fetal cells in the maternal circulation as a means to detect fetal genetic abnormalities.
Throughout its history the Stem Cell Core has provided careful and accurate cell cycle analysis via DNA content analysis using Hoechst dye uptake. This service is still used today by investigators. The facility was among the first to take advantage of the ability to express GFP in cells transfected with vectors and induced to express GFP in transgenic animals conditionally expressing a specific gene promoter. This ability allowed IDDRC investigators to isolate neurons, muscle cells and other cell types which express GFP from those which do not. IDDRC investigators were among the first to subsequently culture sorted neurons. Based on the extensive experience of the core using Hoechst dye for cell cycle analysis, the core was able to help IDDRC investigators prepare side population cells (tissue derived potential multipotent progenitor cells) based on Hoechst dye efflux. These methods have allowed the isolation of different muscle side population cells and have facilitated experiments that aim to use the cells for treating muscle disease. The interactive and collaborative nature of the core has fostered these developments, and the interests of the core director, advisory committee, manager and IDDRC investigators will continue to make this core as innovative in the future as it has been in the past.
The overall goal of the Stem Cell Core Facility is to provide both IDDRC and non-IDDRC researchers comprehensive analytical flow cytometry and cell sorting services in a timely, dependable and cost-effective manner.
The mission of the Cell Resource Core (CRC) at Massachusetts General Hospital is to provide high quality primary hepatocytes and supporting tissues to researchers. We use an innovative, reliable and affordable process that meets Good Manufacturing Process (GMP) standards.
By utilizing a new perfusion technique that was developed at Mass General to preserve the viability of liver cells prior to transplantation, the CRC has been able to increase the viable yield of high quality hepatocytes from donor livers. As a nonprofit resource core, we can provide these cell cultures to researchers at affordable prices.
The Imaging Core provides access to standard digital and laser scanning confocal microscopy, multiphoton microscopy, unbiased stereology, and automated confocal microscopy for large scale genome-wide screens. In addition, the Core has substantial capabilities in quantitative and three-dimensional volumetric image reconstruction.
The Center for Biomedical OCT Research and Translation (CBORT) is a National Biomedical Technology Resource Center (P41) funded by the National Institute of Biomedical Imaging and Bioengineering. Over the past two decades, Optical Coherence Tomography (OCT) has evolved into a powerful microscopy technique that can be used to safely image biological tissue. The mission of CBORT is to enable breakthroughs in biology and medicine through advancements in Optical Coherence Tomography (OCT) technology.
Researchers in the Center for Brain Science (CBS) are discovering the structure and function of neural circuits. We do this to understand:
- how these circuits govern behavior and vary between individuals
- how they change during development and aging
- how they underlie neurological and psychiatric disorders.
To accomplish this mission, CBS brings neuroscientists together with physical scientists and engineers to develop new tools for neuroscience. Members are drawn from the Faculty of Arts and Sciences, the Department of Neurobiology at the Harvard Medical School, the School of Engineering, and the Harvard-affiliated hospitals.
CBS houses a core facility with several scanning electron microscopes.
The SEMs are part of ongoing research to develop a three-dimensional electron microscopy facility, in order to image neural circuits with the highest possible resolution. Traditional methods of serial reconstruction of the brain, in which hundreds of electron micrographs from adjacent slices of a tissue are used to reconstruct the three-dimensional shape of an object, are burdensome. The central objective of the 3D electron microscopy facility is to overcome the technical barriers to serial electron microscopy so that this technique can become as routine as confocal microscopy. We are investigating several approaches to constructing a high-throughput device for generating thousands of serial electron micrographs. With such a tool in hand, investigation of any brain region would be able to include a three-dimensional analysis of the synaptic circuits at full resolution. We believe such a tool will be invaluable for a wide range of neuroscience (and other) questions.
CBS hosts an optical imaging facility that houses advanced devices for widespread use by neuroscientists and is developing the next generation of optical techniques. The optical imaging is intended to be an extension of individual labs, housed in shared space. By pooling equipment, highly skilled technical management of the tools is available, allowing for routine technological upgrades, quicker troubleshooting, and expert advice. In addition, the joint space leads to camaraderie amongst users, and allows new technical advances in one lab to spread rapidly to other labs. This core facility also frees up space in individual labs that can be used in other ways. Finally, the shared equipment lowers barriers to adoption of the latest technology.
This core facility provides:
* Laser scanning microscopes with motorized stages for high throughput reconstructions of the nervous system
* A histology suite for brain sectioning and tissue preparation
* Stereo fluorescence macroscopes
* The newest tools for high-resolution optical microscopy
* Ultra-fast optical scanning microscopes
Technological advances hold a key to greater understanding of the structure and function of complex neural circuits. Neuroengineering is a core facility that provides customized engineering solutions to neuroscience problems faced by our members. Assistance with experimental design, electronics, machining, and software development, are all services provided.
The Neuroimaging facility has a 3-Tesla magnetic resonance imaging scanner for non-invasive human brain imaging. Our aim is to:
* Provide functional and anatomic magnetic resonance imaging (MRI) to scientists studying human cognition, brain development and aging, and individual differences
* Provide training for undergraduate and graduate students destined to become the next generation of neuroscientists
* Pioneer innovative ways of imaging the human brain and is a first adopter of new neuroimaging technology, tools and applications
* Develop and make available the data processing and visualization tools demanded by advancing neuroimaging technologies.
The Center for Cancer Computational Biology at Dana-Farber Cancer Institute provides broad-based support for the generation, analysis, and interpretation of genomic and other large-scale data in the context of basic, clinical and translational research.
The mission of CCGD is to advance precision cancer medicine by developing new technologies for the analysis of cancer genomes and to provide access to these technologies to basic, translational, and clinical investigators. There are three main components:
Technology development: To develop new technologies for the analysis of cancer genomes
Collaborations: To provide access to these genomic technologies to basic, translational, and clinical investigators at DFCI and beyond
Translation: To translate technologies to the clinical setting
CCGD’s services are based on Next Generation Sequencing using the Illumina Hiseq3000, Hiseq2500, and Miseq. Our next-generation sequencing platforms allow for the detection of the full range of genomic alterations, including mutations, structural rearrangements, copy number, and expression changes.
Structure of the Center:
William Hahn, MD, PhD, CCGD Director, Associate Professor of Medicine, Harvard Medical School
Matthew Meyerson, MD, PhD, CCGD Director, Professor of Pathology, Harvard Medical School
Laura MacConaill, PhD, CCGD Scientific Director
Paul Van Hummelen, PhD, CCGD Associate Director
The Center for Clinical Investigation (CCI) is the home for clinical research at Brigham and Women's Hospital. The CCI is committed to facilitating the work of clinical investigators at the Hospital and in the larger community.
The Center for Computational and Integrative Biology is an affiliation of faculty drawn together by a common interest in the study of biology through methods engaging a broader scale of inquiry than the existing standard of the era. The faculty collectively has highly diverse interests, ranging from inquiries into the origins of life, the mechanisms of host-pathogen interactions in plants and model organisms, the relationship between atherosclerosis and inflammatory responses in vertebrates, and the collection and analysis of comprehensive measures of physiology in an attempt to understand the harbingers of adverse outcomes (principally sepsis and its sequelae) in individuals treated for trauma.
The Center for Computational and Integrative Biology provides support for investigators at the hospital and across Boston through a variety of autonomous cores that provide services in DNA sequencing, oligonucleotide synthesis, microarray analysis, and research laboratory automation.
The X-ray diffraction facility in Harvard University offers single crystal X-ray data collection, structure solution and refinement of small molecule structures.
The Center for Human Genetic Research (CHGR) is a multidisciplinary cross-departmental center whose central mission is promotion of the genetic research cycle.
The Center for Macromolecular Interactions (CMI), is a biophysical instrumentation facility for the characterization of macromolecules and their interactions. The CMI mission is to enhance basic research in the HMS community by providing scientific consultation, training and access to shared biophysical equipment. The facility currently includes instruments for Isothermal Titration Calorimetry (ITC), Surface Plasmon Resonance (SPR), Biolayer Interferometry (BLI), MicroScale Thermophoresis (MST), Differential Scanning Fluorimetry (DSF), Circular Dichroism (CD), and Analytical Size Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS).
The Center for Morphometric Analysis (CMA) is dedicated to the development and application of morphometric methods to biomedical imaging data, primarily high-resolution MRI. Using automated and semi-automated software written in our lab, MRI brain images are segmented into anatomical regions of interest. From this, we study the volume, surface, thickness, shape, and location of these regions and combine this with other types of information (behavioral studies, functional-MRI scans, diffusion-MRI, etc.) to analyze both the structure and function of the human brain.
The Center for Nanoscale Systems (CNS) at Harvard University provides staff and resources to acquire, maintain, operate, improve, and develop advanced facilities for use by faculty, students and external collaborators. CNS also provides courses, training, assistance, and collaborative interactions to facilitate use of the equipment.
The intellectual focus of CNS activities is on the operation of its facilities for the fabrication and study of "nanoscale" structures, systems and phenomena that span the range between the atomic and the macroscopic, and whose properties are very different from those of macroscopic systems. These studies include (e.g.):
* Synthesis of nanoscale structures
* Fabrication of mesoscale devices
* Imaging, using electron microscopy and scanned probe techniques
* Advanced optical microscopy
* Biological applications
The Center for Virology and Vaccine Research (CVVR) at Beth Israel Deaconess Medical Center aims to promote research and education activities related to virology, vaccinology, and related disciplines, including basic, translational, and clinical vaccine research. The Center consists of primary and affiliate faculty and focuses on the development of vaccines against infectious, oncologic, degenerative, and other diseases.
The Channing Division of Network Medicine is a research division within the Department of Medicine at Brigham and Women’s Hospital. The Mission of the Channing Division of Network Medicine is: To use an integrated, network-based, systems biology-driven approach to define the etiology of complex diseases; to reclassify complex diseases based on systems pathobiological mechanisms; and to develop new treatments and preventive strategies based on these new disease classifications using systems pharmacology approaches.
The Sargent Award is made possible by the generosity of Dr. Jack Wittenberg through the Charles Sprague Sargent Fund.
We study the molecular biology and genetics of circadian clocks, endogenous oscillators that drive daily rhythms in behavior and physiology. Under natural conditions, circadian clocks become precisely synchronized, or entrained, to the 24-hour light-dark cycle by the action of light on circadian photoreceptors. Together the intrinsic rhythms of the circadian clock and its entrainment to light-dark cycles control the temporal organization of complex behavioral and metabolic programs. In flies and mammals, the master circadian clock regulating behavioral activity is located within specific clock cells in the brain. Of late it has become clear that multiple peripheral tissues in mammals contain circadian clocks, but the roles of peripheral clocks and their relationship to the central clock are not yet understood.
The mission of the Children’s Hospital Boston IDDRC is 1) to focus research on issues of relevance and importance to mental retardation and developmental disabilities, 2) to organize research around clearly defined themes, 3) to accomplish research of the highest scientific merit, 4) to stimulate and facilitate multidisciplinary research with a particular emphasis on combinations of basic and clinical science, and 5) to stimulate and facilitate training in disciplines relevant to mental retardation and particularly to the research themes of this MRRDDC.
The Circulating Tumor Cell Core Facility uses immunomagnetic technology developed by CellSearch to isolate rare tumor cells from whole blood. Isolated tumor cells can then be counted or used for downstream analysis such as molecular studies or flow cytometry.
Neurotransmitters, hormones, and pharmacologic agents act by binding specific receptors or ion channels on the cell surface. We are interested in the structure and function of ion channels, their physiological function, and the signal transduction pathways with which they interact.
Partially funded through Harvard Catalyst, the Clinical Research Coordinator Core is available to support and collaborate with investigators and their research teams in all phases of clinical research, providing services that include assisting with the organization, implementation and completion of clinical research studies.
The Clinical Research Laboratory (CRL) utilizes protocol-driven standard operating procedures for the processing of pharmacokinetics, pharmacodynamic, and biomarker samples. This includes the processing, storage, and tracking of all research specimens to ensure the successful completion of clinical trials associated with patient treatment. The CRL is dedicated to the highest standards of specimen handling to maintain the integrity of data procurement and analysis for clinical trials.
Our laboratory takes molecular approaches to gene regulation and protein function during herpesvirus replication and latency. We conduct these studies to provide excellent models for biological processes in eukaryotic cells and, because herpesviruses are important pathogens, to exploit differences between herpesvirus and cellular processes for safe and effective antiviral therapy.
Areas of research include:
Novel post-transcriptional regulatory mechanisms. Projects include exploring microRNAs, regulated polyadenylation, ribosomal frameshifting, internal ribosome entry sites (IRES's), and translational regulation during herpes simplex virus (HSV) infection.
Herpesvirus DNA replication proteins. antiviral drug targets and prototypes for human replication proteins. Projects include determining the 3-D structures of these proteins (with the Hogle lab) and exploring their interactions with each other and nucleic acids via biochemical, mutational, and biophysical approaches, including (with the Golan and van Oijen labs) single molecule methods. These studies should permit detailed understanding of these complicated proteins and rational drug design.
Drug targets and development of new therapies. Aside from studies of herpesvirus DNA replication proteins, projects include exploiting for drug discovery the human cytomegalovirus protein kinase that phosphorylates the nucleoside analog ganciclovir and the important cellular proteins Rb and lamin A/C investigating how it promotes replication of the virus, and finding new drug targets by a combination of "chemical genetic" and molecular genetic approaches.
HSV latency/pathogenesis. HSV forms latent infections that persist for the life of the host. How this occurs is biologically fascinating and clinically important. Projects entail mutant construction, and PCR-based and microarray methods to explore viral gene regulation (e.g. how microRNAs repress viral gene expression, thereby maintaining latency), and neuronal genes whose expression is altered during viral latency.
The Boston Children's Hospital Computational Health Informatics Program (CHIP) is a multidisciplinary applied research and education program. Informatics has become a major theme and methodology for biomedical science, health care delivery, and public health. Biomedical informatics involves modeling and understanding the cognitive, information processing and communication tasks of biomedical science, medical practice, education and research. The field is inherently interdisciplinary, drawing on traditional biomedical disciplines, the science and technology of computing, data science, biostatistics, epidemiology, decision sciences, population health, omics, implementation science, and health care policy and management. Our faculty are trained in medicine, data scientice, computer science, mathematics and epidemiology.
The CRL was formed with the mission of improving our understanding of the structure and function of the brain and other organs of the human body, in order to improve our capacity to diagnose and treat disease. Members of the CRL achieve this by developing novel technologies and computational modeling strategies for understanding and interpreting radiological images.
Computed Tomography (CT) at Boston Children's Hospital is dedicated to putting children of all ages at ease, as you'll see from the whimsical décor of our Fenway Park and beach-themed CT rooms in Boston and our skilled and child-centered staff at all locations. We are experts at keeping children comfortable and we encourage parents to be in the room during the scan. In addition, our powerful multidetector scanners minimize exam time, often eliminating the need to sedate your child.
Located at two locations: Boston and Waltham. Should be contacted about scanner technology, image acquisition, etc., but not for actual access to the facility.
The function of the Confocal Core is to provide services in confocal microscopy, light microscopy and immunostaining for cells and tissues including:
* Confocal microscopy
* Brightfield and fluorescence microscopy
* Immunoperoxidase and immunofluorescence staining
1. First time users schedule an initial meeting of the P.I., future users and core staff. During this meeting, the project and experimental details will be discussed. Core staff could suggest which microscopy modality works best for the project as well as consultation on strategies to accomplish the imaging task. Users have the option of choosing service work or independent use.
2. Schedule a service work session or a customized microscope training session with one of the core staff members.
The Harvard Medical School EM Facility is a fee-for-service core facility open to all researchers. The Facility provides services and supervision in Transmission Electron Microscopy.
The Deland Award for Student Research is made possible by the generosity of F. Stanton Deland Jr. and the Deland family through the Deland Award Endowment, and by Elise and Marlowe Sigal through the Cunin/Sigal Research Award Endowment.
Our core specializes in conjugating purified antibodies to a 35-metal catalogue for CyTOF users. With over 429 unique markers (261 for human and 168 for mouse), any user can create their own panel from our inventory. We also have optimized protocols specific to CyTOF for cell surface, intracellular cytokine, transcription factor, and phospho-signaling stains. All protocols have upstream specific techniques optimized for single cell population preservation following cryopreservation and through the entirety of the staining procedure.
We are akin to flow cytometry, but we actually utilize mass cytometry (CyTOF).
Current translational research projects in the lab focus on brown and white adipose tissue function, energy balance, clinical physiology, and imaging in collaboration with teams from Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Boston Children’s Hospital, and the Harvard School of Public Health.
1. Integrative physiology: we are conducting studies in both rodents and humans to understand BAT and WAT function and teleology from the molecular and cellular through the epidemiological levels.
2. Noninvasive imaging: new technologies are being developed, including PET/CT, MRI, infrared, and ultrasound, to quantify BAT mass and activity as a way of understanding its structure and function.
3. Therapeutics: physiological and hormonal interventions are being evaluated to identify which ones increase BAT energy expenditure and have the potential for use as treatments for obesity and diabetes.
The CytoGenomics Core provides an invaluable technical resource to the investigators of the BWH, MGH, and affiliated institutions. Services are also available to external academic and commercial laboratories; these should contact us via our website for sample submission and pricing. Cytogenetic studies can provide insight into regions of the genome that are pathogenetic in various neoplasms leading to an understanding of the molecular pathways participating in the biology of cancer. It is appropriate to consider cytogenetics as a fundamental adjunct to a variety of investigations underway, including basic and clinical research. For example, a rather simple cytogenetic analysis of mouse ES cells to determine ploidy prior to injections into blastulas leads to a greater success rate in establishing founders for knock-out and knock-in experiments. The primary chromosomal assignment of a gene by a FISH experiment may lead to correlation of a disease with that gene. Other cytogenetic studies may be important in establishing a diagnosis for correlation with clinical outcome. The advent of molecular probes for FISH analysis has facilitated cytogenetic studies in the mouse, and other model organisms and this Core aggressively implements such technologies.
In addition to state-of-the-art analyses for human samples, the BWH CytoGenomics Core also performs routine mouse karyotyping and a variety of other molecular cytogenetic analyses, services not easily obtainable elsewhere.
The Core provides all of the tools of modern functional proteomics. Equipped with State-of-the-Art technologies for proteomics; protein profiling, protein identification, protein and peptide fractionation, and quantization. Personalized experimental design consultation, comprehensive individualized bioinformatics support.
The mission of the DF/HCC Cancer Proteomics Core is to develop a comprehensive and interdisciplinary proteomics core for High Sensitivity, High Resolution and High Throughput Proteomics with particular emphasis on in depth proteomic consultation, referral to the optimal proteomics facility and a strong focus on clinical sample analysis. The core will combine consultation, service and education into a comprehensive, translationally and clinically oriented proteomics core.
We bring together area resources for functional genomics to create a centralized portal, and provide consultation and educational service. We help researchers navigate available resources for designing, performing, and analyzing functional genomics screens and related assays, and will identify the one or more groups, reagent collections, instruments, etc., available at our participating centers that will best serve your scientific goals.
The Dana Farber Flow Cytometry Core provides state-of-the-art flow cytometry instrumentation in two locations on the DFCI campus. The facilities are managed by a full staff of expert flow cytometry technicians who specialize in assisting researchers with their analysis and sorting needs.
Please visit our website at http://flowcytometry.dana-farber.org/ for more information.
DFCI Medical Arts Core WebLibrary offers complete services for Publications, Presentations and Advertising as follows:
Custom/Computer Graphics illustrations, Design and Consulting full productions services, Photoshop training.
Posters Productions/Brochure Printing on best selection of paper, canvas material and Backlit poster films.
Lamination, LCD announcements creation and posting.
Research Related Photography
* iMAC and PC computers
* Posters printer
* LCD electronic announcements TV units
* Backlit Display units
* Digital camera
The mission of the DFCI Monoclonal Antibody Core (MAC) is to provide immunological reagents (antibodies) to support research efforts of area investigators. We generate and produce novel monoclonal and polyclonal antibodies, recombinant proteins and transfected cells lines for use in basic research, drug discovery and clinical application, including diagnosis, surrogate markers for disease status, and response to therapy or drug toxicity.
Given the diverse research needs of the investigators at DFCI and the surrounding Harvard community, The MAC strives to support a wide range of antibody requests. A key component of the MAC is the ability to explore and develop new technologies that facilitate antibody generation. The MAC is set-up to provide all basic functions of antibody generation, screening, purification (milligram to gram amounts) and storing antibodies.
The DNA Resource Core was started in the spring of 1999 to meet a growing need for DNA sequencing services at a cost that is affordable for academic labs. Our services now include DNA sequencing for large- and small-scale projects and a plasmid repository & distribution service. Our highest priorities are quality assurance, user support and timely request fulfillment.
Questions about the plasmid repository can also be directed to firstname.lastname@example.org. (Please Note: we have drop-off locations in the Longwood Medical Area and at the Harvard Biolabs. Call for pick-ups at MGH Charlestown or other locations.)
Our laboratory is a multinational group located at Children's Hospital Boston. We study development, cellular reprogramming, disease processes, and the improvement of therapeutics with an emphasis on leukemia and genetic blood disorders. These projects build upon basic studies of pluripotent stem cells, the development of blood-forming or hematopoietic tissue, epigenetic regulation, and mechanisms of cancer initiation, progression, and therapy resistance.
Dana-Farber/Harvard Cancer Center (DF/HCC) is the largest comprehensive cancer center in the world, bringing together the cancer research efforts of our seven member institutions: Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital.
Funded by a grant from the National Cancer Institute, we have joined these seven renowned Harvard-affiliated medical centers into one collective force dedicated to the fight against cancer. Based in Boston, DF/HCC consists of more than 1,000 researchers with a singular goal -- to find new and innovative ways to combat cancer.
The Deland Award for Student Research is made possible by the generosity of F. Stanton Deland Jr. and the Deland family through the Deland Award Endowment, and by Elise and Marlowe Sigal through the Cunin/Sigal Research Award Endowment.
The Department of Human Evolutionary Biology at Harvard University asks the question: Why are humans the way we are? We teach and engage in field and laboratory research focusing on genetics, anatomy, physiology, and behavior. We are responsible for both undergraduate and graduate degrees in Human Evolutionary Biology.
Department of Neurology at BWH.
Systems biology is the study of systems of biological components, which may be molecules, cells, organisms or entire species. Living systems are dynamic and complex, and their behavior may be hard to predict from the properties of individual parts. To study them, we use quantitative measurements of the behavior of groups of interacting components, systematic measurement technologies such as genomics, bioinformatics and proteomics, and mathematical and computational models to describe and predict dynamical behavior. Systems problems are emerging as central to all areas of biology and medicine.
The Department of Pediatric Radiology provides a full range of imaging services for newborns, infants, children, teenagers, young adults and pregnant women at Boston Children's Hospital and our satellite clinics in Lexington, Peabody, Weymouth and Waltham. Our experienced radiology team carries out more than 200,000 imaging studies each year, using the latest equipment and techniques specially designed or adapted for use with children.
The DRSC facilitates genome-wide and related Drosophila cell-based and in vivo screening at our state-of-the-art facility. We prove reagents, protocols and consultation throughout the screening process, including help with production of custom RNAi libraries; assay development, optimization and automation; data acquisition; data analysis and integration; and planning of follow-up assays.
Formerly the NERCE NMR Resource. Nuclear magnetic resonance spectroscopy is a powerful tool for studying structural and conformational parameters of molecules. This tool is vital for the chemical analysis of both small molecules (like those discovered in small-molecule screens) and large molecules, such as carbohydrates and proteins found to have potential biologic importance.
In my laboratory, we pursue two interlocking areas of investigation: the basic biology of stem cell programming and reprogramming, as well as the application of the resulting technologies to studies of the neuromuscular system and the diseases that affect it.
Coming to a fundememtal understanding of how a cell's identity is determined during differentiation and how it can in turn be manipulated experimentally, is a central goal of developmental biology, one with susbstantial ramifications for biomedicine. We study both the differentiation of embryonic stem cells into the neural lineage and the reprogramming of commonly available differentiated cell types, such as fibroblasts, into either pluripotent stem cells or cells of therapeutic interest such as spinal motor neurons. To study differentiation and dedifferentiation, we employ a variety of approaches including stem cell differentiation, nuclear transfer and defined reprogramming strategies using known transcriptional regulators and novel small molecule compounds.
A number of devestating diseases, including ALS and SMA specificaly affect the neuromuscular system. Little is known concerning the molecular pathology underlying these conditions at least in part because it has been impossible to access significant quantities of the disease affected cell type, the spinal motor neuron. With recent advances in stem cell and reprogramming biology we can now produce billions of spinal motor neurons with control and diseased genotypes. We use this new resource to design in vitro disease models for both mechanistic studies and for the discovery of novel small molecule therapeutics.
The EM Core at BIDMC provides service, technical assistance, and instrumentation for electron microscopy techniques.
Because EM projects can be extensive and expensive, the EM Core Facility invites all researchers to meet with core staff before a project is started to discuss the scope of the project, how to procure and fix tissues, time line, budgetary concerns, and any other general issues which might arise.
1. Contact the EM core facility staff to schedule an initial meeting. During this meeting, the scientific objectives and experimental details of your project are discussed. Please bring relevant articles that explain the project and any techniques you may be trying to reproduce. Core staff will work with you to design the EM study and schedule work.
2. Users have the option to choose service work (a) or independent usage (b). Please note: The EM core does not offer independent use of core microtomy equipment so the sections must be cut by core staff or elsewhere.
The aims of the EGS are: to assist Center investigators in preparing genomic DNA from blood/buccal swabs collected in their human population studies. This activity involves assistance in the proper collection, extraction, concentration, quality testing and hand or robotic plating for candidate gene and even Genome-Wide studies of gene-environment interaction; to assist Center investigators in creating a genomic DNA biorepository for DNA for genotyping and for epigenetics studies; to assist investigators in obtaining efficient genotyping and epigenetic services either in-house or through partner organizations in the Harvard system; and to assist Center investigators in selection of SNP's, haplotypes, genotyping platforms and for environmental genetic and epigenetic studies of human populations.
The Environmental Statistics and Bioinformatics Core provides intellectual guidance for quantitative aspects of the design and analysis of Center studies. Core faculty and staff have expertise in a full range of biostatistical methods, environmental risk assessment, Geographic Information System (GIS) and spatial statistics, as well as molecular biology, bioinformatics and statistical genetics. Core Faculty are mostly drawn from the Department of Biostatistics at HSPH, particularly the Program in Environmental Statistics, but also from the Environmental Health Department at HSPH.
In addition to providing support for study design and analysis, Core members undertake methodological research motivated by their collaborations with Center investigators. The Core runs a regular seminar series and often sponsors short-courses on specialized topics of interest to the community.
Provides technologies and resources required for studies on polarized epithelial cells that line mucosal surfaces. We provide specialized epithelial cell culture and gene manipulation services, customized materials and instrumentation, expert know-how, and training to facilitate structural and functional studies on polarized epithelial cell culture systems or mucosal intestinal tissue in situ.
"The Exposure and Environmental Analyzes Service provides exposure assessment equipment, design of experimental apparatus, laboratory analyzes of environmental and biological samples, support for methods development and pilot data, as well as training for researchers and students. The service maintains facilities such as clean rooms and exposure chambers."
Specific services are provided by the four affiliated laboratories.
The FAS Center for Systems Biology is dedicated to fostering collaborations both within the center and between it and the outside world, including the wider Harvard community. It is the home of the Bauer Fellows: young, independent researchers, drawn from a wide range of disciplines, and selected on the basis of their willingness to interact with each other, and with the surrounding faculty. The center also maintains extensive laboratory and computer resources in its core facilities, and a core staff to train, assist and collaborate with Harvard researchers wishing to use these resources. The Center for Systems Biology incorporates these two components, and has added a third: an ambitious new initiative to hire up to ten new faculty doing research in systems biology, who can be members of any department in the Faculty of Arts and Sciences.
The Center's overall goal is to combine a variety of experimental and theoretical approaches to find general principles that help to explain the structure, behavior and evolution of cells and organisms. Faculty and Fellows span a wide range of disciplines, including biology, physics, chemistry, mathematics, computer science, and engineering.
The Division of Science strives to provide faculty, students, and staff with the necessary resources to achieve excellence in scholarship and research. Comprised of 230 faculty members and 21 academic departments and units, the Division of Science has more than 1.5 million square feet of space dedicated to scientific research and teaching.
Faculty, students and staff have access to world-class research facilities, instrumentation, funding support, and a variety of workshops, seminars, and lectures. These resources are supported by the Division with the goal of advancing scientific knowledge and inspiring real-world solutions for current and future scientific challenges.
"Committed to meet all of the flow cytometry needs for the BIDMC and the external research community, the Flow Cytometry Core facility offers state of the art instrumentation for routine flow cytometry and cell sorting. It is continuously expanding with the newest software and machinery for both sort and analysis capabilities of up to 30 flourescent parameters. The Flow Cytometry Core facility is available to: answer technical questions; assist you in setting up flow cytometry experiments; assist you with acquiring, analyzing and interpreting your data; assist in data presentation and data storage; provide training on the four benchtop analyzers and on software."
To schedule an appointment for regular flow cytometry (user operated), log onto our online web calendar at: http://bidflow.calendarhost.com/
The Flow Cytometry Core Facility provides high speed cell sorting, multi-color fluorescence cell analysis and data interpretation to Joslin Investigators. The aim of this core facility is to provide a comprehensive service with high quality for scientific researchers. The staff at the facility works closely with investigators to develop new techniques to meet research needs. We welcome investigators interested in developing new modes of analysis.
The core is open to everyone. Different pricing for HSCI vs academic non-HSCI and non-academic institutions.
The Flow Cytometry Facility is a core facility of Schepens Eye Research Institute that provides fluorescent-based cell analysis and sorting to Boston area biomedical researchers.
This lab's mission is "to provide high standard cell sorting and analysis services to the research community at the Brigham and Women’s Hospital and the Longwood Medical area."
The Immunology Division Flow Cytometry Facility provides flow cytometric analysis and cell sorting services to investigators in the Harvard Medical School, The Harvard Stem Cell Institute, and in the Harvard affiliated hospitals and institutions. The facility currently has an LSRII and a FACSCalibur self-run acquisition and analysis for staff trained researchers, and a FACSAria IIu and a MoFlo Astrios EQ for cell sorting (performed by an expert technician).
Flow cytometry access facility. All new users must be trained by the facility manager over two orientation sessions and be approved to use the equipment in the facility.
All users must obtain the financial approval from their PI and financial manager. Please submit a PO number or the Harvard billing code prior to the first use of the facility.
The Flow and Imaging Cytometry Resource provides research flow and imaging cytometry services to all investigators in the PCIMM at Children's Hospital, Boston and Immune Disease Institute, HMS and the local scientific community on a case-by-case basis. With state of the art instrumentation, such as the standard configuration 3-lasers FACSAria located in BL2+-facility, 20-parameters 4-lasers FACSAria SORP and DIVA FACSVantage SE TurboSort™, the facility offers high speed cell sorting and complex analytical services, development of collaborative projects as well as consulting on design and development of new protocols and methods.
The Forsyth Center for Clinical and Translational Research (CCTR) is a unique clinical facility with 6 fully-equipped dental units and associated laboratories that are specifically dedicated to conduct clinical research in oral and related systemic diseases. Clinical trials following FDA guidelines are performed at all levels, from early phase 1 trials to large, multicenter definitive clinical trials, with the goal of improving outcomes and the long-term health of patients. We routinely conduct studies in the oral environment, that include standard clinical measurement protocols for dental caries, dental calculus, gingivitis, periodontal diseases, intraoral local anesthetic evaluation, tooth restoration and tooth whitening evaluation. In addition, the clinic is equipped for obtaining and processing microbiological samples, gingival crevice fluid samples, blood and saliva samples for analysis of bacteria, inflammatory mediators, as well as for genomic and proteomic analyses.
Under the new leadership of Dr. Thomas Van Dyke, Vice President of Clinical Research at The Forsyth Institute, the Center proposes new goals/efforts in discovering new techniques, testing new ideas and searching for valuable biomarkers for preventing and treating periodontal diseases and associated systemic inflammatory conditions. The CCTR is actively involved with the design and conduct of clinical research under Good Clinical Practices for submission to regulatory agencies. It has a published international reputation in evaluating intraoral local drug delivery devices, oral diagnostic systems, local anesthesia, restorative materials, tooth whitening systems and the association of oral diseases with systemic conditions. Forsyth's Institutional Review Board is a member of the Harvard Catalyst Regulatory Group and meets on a monthly basis providing complete review of clinical protocols.
The Biostatistics Core collaborates with clinical and laboratory investigators providing support for experimental design, statistical methods, data analysis and data management for epidemiologic studies, clinical trials and laboratory investigations. Collaborations have included Center grants, Program Projects and numerous individual investigator grants.
These studies have largely focused on oral health research, particularly dental caries and periodontitis, with an emphasis on the microbial and immunologic aspects as well as diagnosis and treatment of these conditions and use of high throughput technologies in their evaluation.
The Forsyth Flow Cytometry Core provides analysis and cell sorting services to all the research laboratories at the Forsyth Institute and the adjacent research entities including Harvard affiliated schools and hospitals.
The core only accept samples to sort if they fulfill the following requirements: 1.) BSL-2 safety level samples or lower 2.) Do not contain free rDNA 3.) Do not contain active virus (ie. confirmed by 7 or more passages or tested for Replication Competent Letivirus with results provided).
The Histology Core provides consulting and support services for both soft tissue and precise hard tissue analysis. Services include: tissue processing, embedding, sectioning, and staining as well as guidance on protocols. The Histology Core can embed samples in standard molds or custom molds in paraffin, resin or as frozen tissue for routine histology, special stains and immunohistological studies performed either by a trained investigator or by Core staff.
The Forsyth Imaging Core specializes in light microscopy for spectral imaging and imaging of clarified tissue samples.
Founded in 1910 as a dental infirmary for disadvantaged children, the Forsyth Institute has a proud history of not just meeting the oral health needs of kids – but exceeding the traditional limits of oral medicine.
In the mid-1900s, researchers at Boston-based Forsyth revolutionized the oral health profession when they discovered the connections between dental decay and bacteria. Building on these revelations, the Institute has become an independent research organization dedicated to advancing human health and well-being through scientific discovery and education.
Although our hallmark is the study of oral health, our focus has widened over time to include the investigation of such diverse areas as diabetes, cardiovascular disease, and regenerative medicine. We have adopted this multidisciplinary research approach in order to analyze and prevent the severe systemic ramifications of oral infections.
The world's most trusted authority in our field, we have a reputation for redefining convention – and we've made a century-long commitment to the community. Our work has inspired our profession to re-examine the scientific basis for oral disease. Today, the gifted scholars from around the globe who join our quest are dedicated to achieving a new generation of breakthroughs in oral health and disease prevention.
Forsyth, an independent non-profit organization, is affiliated with Harvard School of Dental Medicine and Harvard Medical School and has collaborations with university and research organizations around the world.
The Forsyth Micro Computed Tomography (μCT) Core offers micro 3D X-ray imaging of small samples in high resolution, and will provide images and quantitative analyses of internal structures of ex vivo samples without any destructive procedures. The Scanco μCT40 system allows for visualization, measurement, and quantification of the structure of mineralized specimens. Contrast reagents permit visualization of structures such as blood vessels. This system creates a three-dimensional model from a stack of two-dimensional X-ray images taken around a single axis of rotation. The high-resolution scanner can capture detail at a resolution of 6 to 32 microns. The non-destructive nature of this technology allows investigators to carry out complementary analyses (e.g. histology) of the same samples.
The FAC represents a strategic interdisciplinary alliance between the Muscle Mechanics and Metabolomics Laboratory and the Laboratory of Exercise Physiology and Physical Performance at Brigham and Women’s Hospital, Harvard Medical School, and the Nutrition, Exercise Physiology and Sarcopenia Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. The core provides standardized, state-of-the-art technologies to measure muscle performance, physical function, and disability in human and animal studies for OAIC’s pilot and exploratory projects and for several OAIC related projects funded through other sources.
The Laboratory of Exercise Physiology and Physical Function at BWH is a 1,000 square foot laboratory that includes private exam rooms, rest/changing room, and work stations for research staff. The Laboratory is staffed by two Master’s degree level Exercise Physiologists and a Research Assistant. A physician Medical Director provides general oversight. The laboratory has substantial experience in conducting and overseeing clinical trials in young adults as well as older persons with mobility limitations, fall history, and chronic diseases. The designated exercise space is equipped with state-of-the-art equipment are illustrated below.
Research in our laboratory is committed to expanding our molecular understanding of the formation and regeneration of tendons and ligaments. Injuries to tendons and ligaments result in a slow and imperfect regenerative response. In most cases, the original biomechanical properties of the tissue are never restored, resulting in scarring and limited mobility. We use a multidisciplinary approach, combining genetic and chemical screening with different model systems such as zebrafish and stem cells, to identify essential regulators of tendon and ligament biology.
One major area of research in the laboratory aims to identify the cues that direct progenitor cells to become mature tendons and ligaments. During embryogenesis, progenitor cell populations will form the tendon or cartilage tissues in our limbs, head and spine. We are interested in elucidating the pathways that regulate this fate decision, expand tendon and ligament populations, and promote more faithful differentiation into these lineages.
We are also focused on understanding the critical factors that coordinate the attachments between muscle, tendon, and bone. By combining live-imaging and high-throughput screening approaches, our goal is to identify the molecules and cellular behaviors governing these processes. In the long term, my laboratory aims to transform these discoveries into regenerative biology solutions to better heal and repair tendon and ligament injuries.
Hanna Gazda's research focuses on identifying the genetic causes and molecular pathogenesis of Diamond-Blackfan Anemia (DBA), a bone marrow failure characterized by anemia, bone marrow erythroblastopenia and congenital abnormalities. The first DBA gene, ribosomal protein S19, was found to be mutated in ~25% of DBA patients. Gazda and colleagues recently identified four other genes, RPS24, RPL5, RPL11, and RPS7, mutated in ~15% of DBA patients, and confirmed that DBA is a first human disease caused by mutations in ribosomal proteins. They also discovered the first known correlation between mutations in certain genes and particular clinical findings. In particular, mutations in RPL5 are associated with multiple physical abnormalities including cleft lip/cleft palate, thumbs and heart anomalies, while isolated thumb malformations are predominantly present in patients carrying mutations in RPL11. The laboratory’s current goal is to identify other genes involved in DBA, to uncover the pathogenesis of the disease and to generate an animal model for DBA.
Raif Geha's lab pursues the molecular basis of inherited immune deficiencies. The Geha lab has established a mouse model of Atopic Dermatitis and is studying the mechanisms of allergic sensitization through the skin and of recruitment of T cells & eosinophils to the skin. The researchers are pursuing several investigational avenues. One seeks to identify the molecular process by which a B cell switches from producing one class of antibody to another. A second explores inherited immune deficiency disorders, with special emphasis on Wiscott-Aldrich Syndrome. A third investigates the molecular basis of atopic dermatitis (AD) a common, an allergic inflammation of the skin that is common, but poorly understood. The lab has created an animal model of AD that may ultimately be used to develop potential drugs.
Isotype switching is the mechanism by which a B cell goes from producing one type of antibody to another while maintaining antigenic specificity. This phenomenon allows the immune system to produce various antibody types against the same antigen, but having different effector functions. Isotype switching is a highly orchestrated process with several cytokines and T and B cell surface molecules participating. The Geha laboratory has shown that B cell surface molecules CD40, BAFF and APRIL are important for the switching process, and that defects in these molecules, or in the signaling cascade emanating from them, could potentially lead to immunodeficiency. Geha and colleagues have also shown that C4BP, a complement regulatory protein, binds to CD40 and induces isotype switching. At present, they are studying the role of BAFF and APRIL in isotype switching and antibody affinity maturation.
Wiskott-Aldrich syndrome (WAS) is a primary immunodeficiency caused by mutation in the gene encoding for the WAS protein (WASP). The Geha group identified a novel cellular negative regulator of WASP they have named WIP. WASP and WIP together regulate most cell functions that require the remodeling of the actin-based cytoskeleton--the structural framework of the cell. The Geha lab is now studying the role of WASP and WIP in immune cell functions that require active cytoskeletal remodeling such as migrating in response to chemical signals and homing. They are also mapping the domains of WASP and WIP that are involved in discrete functions of these molecules.
Our primary goal is to provide high titer, high quality research grade viral vectors to the research community at Harvard, within Boston, and outside to support preclinical gene therapy studies and basic research gene transfer applications.
The Genetically Modified NOD Mouse Core provides Center investigators, as well as researchers elsewhere, with access to transgenic and mutant lines derived from the NOD mouse model: some will be generated within the Core; others are established lines of proven experimental value that are maintained in the Core.
The Core will construct transgenic mice in strains that have a high susceptibility to diabetes (in particular in the NOD line). This includes trangenesis by conventional pronuclear injection or by delivery of RNAi cassettes on lentiviral vectors.
The Core will also provide a panel of existing transgenic and mutant lines. These lines are chosen because of their established interest in allowing the dissection of immunological tolerance in Type 1 Diabetes, and in response to Center investigator needs.
The Genome Engineering and induced pluripotent stem cell Center (GEiC) supports researchers with up-to-date technologies to meet their cell and animal model needs. On the genome engineering front, we offer a variety of services tailored to best fit investigators individual preference, ranging from CRISPR reagents with or without validation, to cancer/iPS cell line modification or animal model creation. We work closely with mouse cores from design, reagent validation to genotyping, process improvement and troubleshooting, when necessary. We also provide next-generation sequencing (NGS) based human cell authentication and NGS-based genotyping services and general molecular biology assistance. On the iPSC front, we culture, bank and store primary fibroblasts and renal epithelial cells from patient samples for investigators, and iPSC reprogramming service is provided from fibroblasts, RECs as well as peripheral blood mononuclear cells (PBMCs). The GEiC aims at helping investigators convert their idea to a useful model quickly and cost-effectively.
The Genome Modification Facility (GMF) provides transgenic, gene targeting, and other services to investigators of Harvard University and its affiliated institutions, as well as to investigators within the US and abroad. The GMF performs microinjections of DNA into fertilized embryos to generate transgenic mice, DNA transfection into ES cells for the creation of recombinant ES cell clones, injection of gene-targeted ES cells into host blastocysts to generate gene knock-out or knock-in mice, teratoma formation studies, and other related ES cell-based services. Other services include cryopreservation of mouse sperm and embryos, in vitro fertilization (IVF), recovery of cryopreserved mouse sperm and embryos, rederivation of pathogen free mouse lines, and derivation ES cell lines from wild type and mutant mice with a variety of genetic backgrounds. Our staff provides general consultations on experimental designs and vectors for gene modification-related projects, DNA preparation, recombinant ES clones, mouse genotyping, colony breeding and husbandry. We can also customize services as requested to support development of animal models of human diseases.
The mission of the Genotyping and Genetics for Population Sciences Core is to provide services to investigators conducting molecular analyses of somatic DNA collected as part of a wide range of investigations. This Core provides high-throughput assays of specific gene mutations and polymorphisms (SNPs) in the many situations where previously defined specific nucleotide alterations are of interest.
The Glycomics Core provides services, instrumentation and expertise in glycomics to BIDMC research groups, affiliated and non-affiliated institutions and corporate companies.
We are interested in developing and applying new technologies in the fields of mass spectrometry and proteomics. The impressive amount of data generated by the genomics revolution is being organized and made accessible in a variety of databases and libraries. These include genomic and expressed sequence tag databases, transcriptome maps, and protein databases that describe the identity of some of the proteins expressed by a tissue or cell, as well as other relevant properties including their structure, function and macromolecular interactions. Many of these databases describe the situation encountered at the time of the measurements in a static manner. However, many biological processes are dynamic responses to extraneous perturbations, be they environmental, pharmacological, pathological, genetic or otherwise. The ability to detect accurately and to quantify all of the changes included by a specific perturbation is therefore an essential part of the study of dynamic biological processes. At the heart of all aspects of our lab is protein sequencing by mass spectrometry. Simplified greatly, a tandem mass spectrometer can "sequence" a peptide ion by first measuring the mass of the peptide and then selectively isolating and gently fragmenting that peptide at peptide bonds followed by mass measurement of the fragment ions. The resulting tandem mass spectrum contains the sequence information for a single peptide. The astounding power of the technique can be understood when one compares traditional peptide sequencing by Edman degradation with peptide sequencing by mass spectrometry. A decapeptide can be sequenced by Edman degradation in about 12 hours. That same peptide can be sequence by a tandem mass spectrometer in about 1 second at 10 to 100 times the sensitivity.
Provides resources in immunofluorecence, electron microscopy, confocal, and deconvolution microscopy of living and fixed cells and tissues, and offers expertise in imaging polarized cells in monolayer culture
There are 3 locations for Core B:
* Immune Disease Institute (IDI)
* Children's Hospital Boston (CHB)
* Beth Israel Deaconess Medical Center (BIDMC)
The HMS Microfluidics Facility aims to make the tools of Microfabrication and Microfluidics available to all HMS users.
The Research Instrumentation Core Facility enables the development of new scientific instruments in order to further research at Harvard Medical School and affiliated institutions. Special preference is given to projects intended to generate novel instruments for cutting-edge research in neuroscience and the root causes of neurological dysfunction.
Our facility houses two state-of-the-art BD analyzers with high-throughput capability, a Stratedigm benchtop analyzer, a high-speed BD cell sorter, and both Mac and PC workstations for data analysis. Sorting services are offered through the facility, as well as instrument and software training.
There is a growing need for animal models to carry out in vivo developmental and regenerative medicine studies of human cells, tissues and organs. The Humanized Neonatal Mouse Center (HNMC) was created to accelerate research in the stem cell field by providing humanized mouse models to study human stem cell engraftment and differentiation in regenerative medicine. We have over 4 years of experience in constructing different types of humanized mouse models, including neonatal heart, lung and kidney injury models. We have extensive experience in hematopoietic stem cell reconstruction. It is our goal at HNMC to facilitate collaborative research in human stem cell biology, where physiologically relevant microenvironments (niches) may be created in vivo to study human stem cell fate and function under experimental settings where disease, damage or degenerative conditions can be controlled. We can provide customized humanized mouse models to the HSCI research community, to collaborate on research studies of common interest, and to advance the general use of these models for a broad range of translational and preclinical studies.
The HSCI iPS Core facility was created to accelerate research in the stem cell field by facilitating the derivation and distribution of iPS cell lines. Disease-specific iPS lines provide us with a unique opportunity to study the mechanisms of disease and ultimately to develop new treatments. The iPS Core serves as a repository for iPS cells produced by HSCI scientists and functions as a laboratory to produce disease-specific lines for sharing with the HSCI and broader research community.
The lab is committed to meeting all the flow cytometry research needs of the HSCI, BCH, DFCI and Harvard communities. We are continuously improving our equipment and software to bring the latest instrumentation and capabilities to our users for cell sorting and analysis. Since being established in August of 2008, under the Direction of Ronald Mathieu, Ph.D, ASCP, the lab has contribute to a significant amount of publications and brought forth many collaborations.
The HSCI-CRM Flow Cytometry Core Facility seeks to provide high quality, accessible cytometry sorting and analysis services to laboratories in the Center for Regenerative Medicine, Harvard Stem Cell Institute, and MGH research communities at an affordable rate. The Core's equipment and highly trained operators provide an advanced level of sorting and analysis services to its investigators. Additionally, the Core is dedicated to training users on all aspects of flow cytometry, including basic theory, information about specific applications, and critical interpretation of sorting results. The Core's four full-time staff members strive to ensure that each investigator's visit benefits their individual experiments to the greatest extent possible. To ensure the best availability to all users, the Core offers an online scheduling system, and provides extended sorting hours until late evening.
HSCI faculty have reduced pricing for use of the Core's services.
The HSPH Microbiome Analysis Core (HMAC) provides analyses of microbial amplicon (16S rDNA and ITS), metagenomic, metatranscriptomic, and metaproteomic sequence data. The HMAC offers support at all stages of research, from study design through proposal drafting to data analysis and interpretation. Core activities include consultation, provision of services, and fully collaborative grant-funded investigations.
The HMAC has extensive experience with large cohort-based multi’omic data collections, from bioinformatics processing to systems biology and integrative data analysis. We also carry out analysis of individual microbial genomes, and maintain a richly annotated catalog of all currently available microbial genomes as well as a large database of cross-species microbial functional data.
The Harvard Catalyst Clinical Research Center (HCCRC) provides state-of-the-art clinical research facilities and expertise to faculty who conduct human studies.
For a comparison table of offerings at the five HCCRC sites, as well as details and contact information for each site, see: http://catalyst.harvard.edu/programs/hccrc/hccrc-sites.html
Harvard Catalyst | The Harvard Clinical and Translational Science Center is dedicated to improving human health by enabling collaboration and providing tools, training and technologies to clinical and translational investigators. Founded in May 2008, Harvard Catalyst is a shared enterprise of Harvard University, its ten schools and its seventeen Academic Healthcare Centers (AHC), as well as the Boston College School of Nursing, MIT, Harvard Pilgrim Health Care, and numerous community partners.
Harvard Catalyst is a member of the NIH-funded Clinical and Translational Science Award (CTSA) Consortium, and shares tools, technologies, and best practices with other consortium members locally (i.e., Boston University, Tufts University, University of Massachusetts Medical School) and nationally.
Harvard Catalyst resources are available to all Harvard faculty, regardless of their institutional affiliation or academic degree.
The Harvard Center for Biological Imaging (HCBI) was created to foster collaborative research in the most state-of-the-art facility available. To do this, a unique partnership with Carl Zeiss Microscopy has been established in which microscopy systems are replaced every 2-3 years, ensuring access to only the most up-to-date imaging systems. The facility is open 24 hours/day, 7 days/week and access to the HCBI is open to all academic and industrial researchers.
The HSPH Bioinformatics Core (HBC) offers consultations on basic questions in research computing, bioinformatics and computational biology during the initial stages of study design and grant proposals as well as for ongoing, funded studies requiring external expertise.
HBC has experience in large-scale data management, database design and software development. Staff members can provide assistance in quality assurance and analysis of gene expression arrays, genome-wide SNP arrays, CNV studies and different aspects of second-generation sequencing technologies such as ChIP-seq, RNA-Seq or resequencing efforts.
Services also include provision of external information generated from public database, data curation and assistance on choosing the right data format and annotation standard to ensure best practices in data management and submission are being maintained.
Harvard College adheres to the purposes for which the Charter of 1650 was granted: "The advancement of all good literature, arts, and sciences; the advancement and education of youth in all manner of good literature, arts, and sciences; and all other necessary provisions that may conduce to the education of the … youth of this country." In brief: Harvard strives to create knowledge, to open the minds of students to that knowledge, and to enable students to take best advantage of their educational opportunities.
The Harvard Digestive Disease Center is a community of scientists focused on the study of epithelial cell function and mucosal biology in inflammation, host defense, and cancer of the gastrointestinal tract and related mucosal surfaces. The Center aims to facilitate multidisciplinary research in this field by providing technical resources, core services, scientific expertise, and an important meeting point to foster close scientific and intellectual relationships among independent investigators in Harvard-affiliated hospitals, the Harvard Medical School and adjacent research institutions in the Longwood Medical Area.
Harvard’s Faculty of Arts and Sciences (FAS) is dedicated to delivering an unparalleled student experience, redefining liberal arts education for the 21st century, and advancing knowledge for solutions and scholarship. The FAS is also committed to an open Harvard and student aid by making a Harvard education accessible to students from all backgrounds.
Founded in 1890, the FAS is the largest division of the University and comprises Harvard College and the Graduate School of Arts and Sciences, including undergraduate and graduate admissions; the School of Engineering and Applied Sciences; and the Division of Continuing Education, including the Extension and Summer Schools. The FAS also encompasses academic resources such as libraries and museums, as well as campus resources and athletics.
The Harvard Gene Therapy Initiative was founded with the objective of promoting the use of gene therapy in both research and therapeutic applications and to conduct research developing new gene delivery vector technologies.
The Harvard NIEHS Center for Environmental Health serves as the primary focus for environmental health-related research and training activities in the Harvard School of Public Health, in the Harvard Longwood Medical Area, and more broadly as an integrating umbrella for environmental health research in the Boston health sciences research community. The Center was established in 1958 to foster collaborative arrangements that cross-departmental and institutional boundaries to promote interdisciplinary research projects.
The Harvard NeuroDiscovery Center is a pioneering biomedical research group focused on ending suffering from neurodegenerative diseases. By drawing on the intellectual strength and proven capability of the Harvard medical community and colleagues throughout the world, the NeuroDiscovery Center has developed a unique approach to understanding and treating these devastating diseases.
* Alzheimer's, Parkinson's, multiple sclerosis, ALS (amyotrophic lateral sclerosis) and other degenerative diseases of the brain.
* Combining academic creativity with a business-like approach to ensure a focused and efficient effort to advance the search for cures.
* Accelerating the pace of progress, from scientific discoveries to meaningful patient treatments.
* Real collaboration across the Harvard Medical community, prominent research centers worldwide and the private sector.
* Applying discoveries about one neurodegenerative disease to better understand the others.
The NeuroDiscovery Advanced Tissue Resource Center (ATRC) provides state-of-the-art molecular pathology resources to the Harvard community. Current resources include laser capture microscopy, DNA/RNA/miRNA quality/expression analysis, Luminex FlexMap 3D multiplex bead cytometry, and real-time PCR.
Users should use the ATRC online calendar to check instrument availability prior to booking time. All booking is done directly with ATRC staff.
The ATRC is a fee-for-use facility. For NeuroDiscovery members, the first 10 hours of training, consultation and instrument use is free. This initial period is intended to provide a first time user with preliminary data/proof of concept regarding their project, and is generally sufficient when investigators work under the aegis of ATRC staff. Thereafter, the base fee varies depending on activity and the extent of your proposed work. Project-based charge-back agreements for large projects can be negotiated with the ATRC Director, Dr. Charles Vanderburg.
Before using the facility, investigators are required to submit an ATRC user form including a brief research summary of their proposed project to the core director. For more information, or to schedule your initial visit, please contact the ATRC.
Although priority is given to NeuroDiscovery members investigating neurodegenerative diseases and the CNS, the facility is also available to any academic investigators within the Harvard medical community and the greater-Boston research community. Under special arrangements the facility may also be made available to the commercial sector. Please contact ATRC Director, Dr. Charles Vanderburg, for details.
The Harvard NeuroDiscovery Center Biomarker Study aims to discover and validate biomarkers for neurodegenerative diseases.
High quality statistical support is important in the preparation of grant applications or study protocols for clinical trials. Such support typically is not readily available to investigators who are new to clinical trials. To address this weakness, the NeuroDiscovery Center provides consulting and collaborative services to its members who are engaged in clinical research applicable to neurodegenerative disease.
The Enhanced Neuroimaging Core offers comprehensive training, consultation and support throughout every phase of an imaging experiment. Image acquisition is available on several systems offering confocal, multi-photon, epi-fluorescence, brightfield, DIC, phase contrast, and 6D live cell imaging. Image analysis is supported through several high-end analysis platforms. Please contact Lai Ding, the optical imaging manager, or Daniel Tom, the optical imaging specialist to discuss your imaging needs.
"The Harvard University Office of Technology Development (OTD) provides a one-stop shop to advance the development of groundbreaking discoveries by fostering strategic collaborations with industry through licensing, sponsored research and new venture agreements.
Our specific objectives include:
* Ensuring that Harvard research results are made widely available and transformed for public use and benefit.
* Serving as a dynamic bridge from laboratory to industry to make certain that promising new technologies are translated into products and services that benefit society.
* Evaluating, patenting and licensing inventions and discoveries made by faculty of Harvard University, Harvard Medical School, Harvard School of Public Health, the School of Engineering and Applied Sciences, and the Wyss Institute.
* Stimulating innovation and technology development within the Harvard community and securing all necessary protection of the resulting intellectual property.
* Licensing Harvard technologies to strong, effective partners.
* Establishing start up ventures and building value around Harvard innovations.
* Building sponsored research collaborations with industry around faculty-initiated applied research projects."
Keywords: micro/nanotechnology, drug discovery, chemicals and materials, energy, engineering/communications, stem cells/regenerative medicine, medical devices, medical diagnostics, therapeutics/vaccines, disease areas, genomics/proteomics
The Harvard Pilgrim Health Care Institute’s Department of Population Medicine is a unique collaboration between Harvard Pilgrim and Harvard Medical School. Created in 1993, it’s the only appointing medical school department in the United States based in a health plan.
In 2004, Harvard University announced the establishment of the Harvard Stem Cell Institute, a collaboration of world-class scientists from the university and its affiliated hospitals dedicated to advancing stem cell science and building a foundation for the future of regenerative medicine. HSCI is a networked organization that was formed to bridge the gap between academic research and real-life medical applications, to truly go from “bench to bedside.”
The Harvard community is one of the largest concentrations of biomedical researchers in the world. HSCI has united over 70 stem cell experts among its principal faculty alone, making it many times larger than any other major stem cell research institution in the world. This depth and breadth of expertise in a geographically constrained area enables people to collaborate closely. This has allowed HSCI as a group to achieve results such as creating more ESC and iPS cell lines and publishing more papers in the leading journals than any other entity. Even more unique among such institutions, HSCI includes affiliates from professional schools in public health, business, law, and public policy.
The overarching mission of the Harvard T.H. Chan School of Public Health is to advance the public’s health through learning, discovery, and communication.
The Graduate School of Arts and Sciences is where scholarship and innovation meet, where ideas are challenged and theories developed, where new knowledge is created, and where scholars emerge.
The Health Communication Core offers a full range of creative communication services to support evidence-based recruitment and retention of study participants and intervention research. HCC serves researchers from diverse disciplines who need websites, logos, brochures, social media campaigns, publications, and interactive media targeted to the needs and preferences of specific audiences.
or more than 50 years, the Institute for Aging Research has initiated hundreds of studies that challenge health-related assumptions commonly associated with aging. Our findings have a direct and positive impact on the standard of care and quality of life for seniors around the world.
We are a research affiliate of Harvard Medical School and our highly regarded researchers collaborate with other renowned health care institutions around the world. As a part of Hebrew SeniorLife, our goal is to further our shared mission to redefine the aging experience.
The High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Core Facility offers measurements of the microscopic internal structure of cortical and trabecular bone in the distal radius and tibia. Additionally, the HR-pQCT Core Facility offers Finite Element Analysis to estimate key biomechanical properties of the bone including failure load and stiffness.
By scanning the distal radius and tibia, the HR-pQCT Core can measure a variety of important parameters reflecting the integrity or cortical and trabecular bone. This information cannot be determined using standard clinical imaging techniques such as dual-energy x-ray absorptiometry (DXA). A scanning appointment is a 30 minute addition to a clinical research visit and involves less radiation exposure than traditional bone densitometry. With applications for both cross-sectional and longitudinal research, investigators have employed our facilities and expertise to study a variety of bone-related diseases with participants ranging in age from children to the elderly.
The goal of the HR-pQCT Core is to provide facilities and personnel on a per study basis, allowing investigators access to important information about bone structure and function without requiring special expertise and equipment.
Getting Started: To begin organizing a cohort for HR-pQCT studies or to inquire further, please contact the Core Director, Dr. Joel Finkelstein.
The function of the Histology Core is to provide services in paraffin histology for cells and tissues including:
Work is done on a fee-for-service basis with a graded fee structure.
Supplemental funding is provided by BIDMC and the Harvard Digestive Disease Center (HDDC). Priority use and reduced fees are given to investigators with these affiliations.
HHMI, a nonprofit medical research organization that ranks as one of the nation’s largest philanthropies, plays a powerful role in advancing biomedical research and science education in the United States. The Institute spent $776 million for research and distributed $1.6 million in grant support for science education in fiscal year 2010.
The Human Neuron Differentiation Service (HNDS) is one component of the Human Neuron Core, comprised of the HNDS and the Assay Development and Screening Facility (ADSF), that will exploit transformative stem cell technology for both modeling of specific diseases and screening of test compounds in human neurons derived from induced pluripotent stem cells (iPSCs). The goals of this service are to: (1) develop standard operating procedures for the generation of different types of neuronal cell lines; (2) create neuronal cell lines from iPSCs derived from patients with specific diseases and from healthy controls; (3) compare key characteristics (e.g. shape, growth, synaptic connectivity, protein composition) of patient-derived and control-derived neurons; (4) identify disease-specific characteristics in patient-derived neurons; (5) screen drug candidates in disease-specific cell lines to greatly increase the speed and specificity of drug discovery; and (6) compare results of these “pre-clinical” drug trials with clinical trials in patients.
We provide reproducible quality-controlled preparations of neurons that release preclinical research lab personnel from labor required for neuron production to focus on the execution of cutting edge research. The core can receive iPSC lines under IRB approval from patients characterized by clinicians in other Massachusetts hospitals. The phenotyping service will be of particular value to clinical investigators who work closely with patients, but may lack basic science skill sets needed to establish iPSC lines, derive specific neurons from these and conduct sophisticated phenotypic analysis.
The Human Sample Procurement Core will support translational research endeavors within the JDRF Center by providing the Center's laboratories access to well-characterized blood samples from patients with diabetes at different stages of the disease. This availability will greatly facilitate the translational exploration of concepts and targets emerging from the basic research projects.
Individuals with T1D (recent onset, long-standing Type-1 diabetes) and matched controls (healthy or T2D) will be recruited from the patient population at the Joslin Diabetes Center and neighboring institutions. The Core will perform and record a basic characterization of patients and their samples. This analysis will include a thorough evaluation of clinical characteristics from a diabetes and autoimmune standpoint, and an immunogenetic workup (outsourced to Joslin or other cores): autoantibody determination, HLA typing and genotyping for the best recognized susceptibility loci (INS, PTPN22, CTLA4). A relational database will be adapted to record all patient information, copies of which will be provided in a de-identified manner to the investigators.
The ICCB-Longwood Screening Facility provides resources and assistance for designing, conducting, and interpreting high-throughput chemical and siRNA screens. ICCB-Longwood is staffed by full-time personnel with expertise in lab automation, biochemistry, cellular and molecular biology, microbiology, HTS microscopy, and data analysis. The facility employs a staff-assisted screening model, in which investigators using the facility are provided with access to compound and siRNA libraries, and training in the use of some instruments, such as liquid handling equipment, plate readers, and screening microscopes. Staff members provide assistance at all stages of the screening process and perform complex automation steps.
The Image Management Core provides software and services for the storage, management and sharing of microscope images and metadata.
IDAC provides image data analysis services to individual labs and core facilities at Harvard Medical School, including the ICCB-Longwood Screening Facility (ICCB-L), the Drosophila RNAi Screening Center (DRSC), and the Nikon Imaging Center (NIC).
Imaging Solutions for Scientific Communication positions digital imaging resources right where the research is being done: in Harvard Medical School's quad-based basic science departments. The convenience of these locations makes it easy for researchers to access digital imaging expertise when faced with research imaging questions. This accessibility and convenience is supplemented by substantial web-based assistance, making Research Imaging Solutions a 24/7 resource. Seminars, Workshops and printed training materials guide faculty, students, post-docs and lab personnel on supported imaging hardware and software products. Supported hardware and software packages includes: Adobe products including Acrobat, Photoshop, and Illustrator; ACD Canvas; Microsoft Office applications including Word, PowerPoint and Excel; film recorders, slide and flatbed scanners, and color output devices such as color laser printers, poster printers and photo quality printers.
Induced pluripotent stem cells (iPS cells), generated by transcription factor-dependent nuclear reprogramming of differentiated somatic cells, are pluripotent stem cell lines that can be propagated indefinitely in culture and maintain the potential to differentiate into any cell type in the body. As iPS cells retain the same genetic make-up as the somatic cell targeted for reprogramming, these cells hold tremendous promise for uncovering novel genetic and biochemical factors that underlie diseases with complex and poorly understood genetic influences, such as diabetes. The newly established iPS Core maintains a centralized facility for the reliable and consistent generation and propagation of reprogrammed iPS cells for use in cutting-edge research into the molecular and cellular pathologies underlying diabetes and its complications.
Analysis of air pollution samples: including gravimetric determination of particle mass from filter samples; chemical analysis for passive and active samples of pollutant particles and gases; instrumental analysis of elemental and organic carbon collected on quartz fiber filters; trace elemental analysis of filter samples, and ; reflectance analysis of atmospheric black carbon.
The Integrated Health Science Facility Core is composed of three facility services:
* Environmental Genomics Service Facility
* Biological Analysis Service
* Exposure and Environmental Analysis Service
The main objective of the Islet Isolation Core is to provide Islets of Langerhans to investigators in the Boston area and beyond. By receiving islets from the Core one is assured of consistent high quality and purity of islets for experiments. The Core can isolate rodent and neonatal porcine islets. This leaves the investigator to concentrate on experiments rather than the complexity of islet isolation.
Affiliated with Harvard Medical School.
The Jewett Prize is made possible by the generosity of Prof. James R. Jewett through the James R. Jewett Fund.
Joslin's research team represents the most comprehensive and dynamic research program dedicated exclusively to diabetes anywhere in the world. More than 300 scientists are committed to pursuing innovative pathways of discovery to prevent, treat and cure type 1 and type 2 diabetes and their complications.
The Diabetes Research Center (DRC) has been funded by the NIH/NIDDK since th late 1980's and it's presently in its 26th year of funding. The primary aim of the Joslin DRC is to provide a facilitating framework for conducting multi-disciplinary basic and clinical research and to encourage the scientific development of young investigators. Special attention is paid to fostering rapid translation of basic research to the next level.
This is accomplished by the three major programs of the Joslin DRC:
1. Core Laboratories which provide services, reagents, specialized technical expertise and education directed at enhancing the productivity of research programs.
2. Pilot and Feasibility projects that support the development of new investigators and allow established investigators to explore new areas, and strengthen bridges to surrounding institutions.
3. The Enrichment Program which provide a series of seminars, workshops and visiting professors to provide continuing education, stimulation, and foster collaborations with external research programs.
The broad interest of my lab is to characterize the biology of stem cells in the normal lung and in lung cancer using a combination of mouse genetics, cell biology and genomics approaches. Our lung stem cell studies are focused on a population of adult stem cells in murine lung, bronchioalveolar stem cells (BASCs), which we hypothesize are crucial for lung injury repair in adults. We initially showed that BASCs have the potential to differentiate into bronchiolar and alveolar lineages in two-dimensional cultures. We recently created unique three-dimensional systems that demonstrate the ability of BASCs to produce bronchiolar and alveolar structures in culture and in vivo after subcutaneous injection. We have also used genetic lineage tracing studies to demonstrate the potential of BASCs to mediate alveolar cell repair in vivo. We have developed transplant assays to deliver lung stem cells and several new mouse strains, which now allow us to track the fate of BASCs after injury or in lung disease contexts. Our new assays for studying the self-renewal and differentiation potential of lung stem cells are making it possible to address critical areas in lung biology.
Our work has identified novel molecular regulators of lung stem cells. We demonstrated that the Polycomb protein Bmi1 is required for self-renewal of BASCs, repair of lung injury, and lung tumorigenesis (Dovey et al, PNAS). This work uncovered a much broader role for Bmi1 in adult stem cell function and tumorigenesis than was previously appreciated. More recently, we determined that p57 and a large subset of imprinted genes are Bmi1 target genes. We found that these imprinted loci are key regulators of lung stem cell self-renewal, uncovering a whole new set of stem cell regulatory genes that are likely needed in diverse adult tissue-specific stem cells (Zacharek et al, Cell Stem Cell).
My lab has also made key advances in elucidating the biology of stem cells in lung cancer. We discovered an important link between the genetic status of lung tumors and the phenotype of the tumor-propagating cells (TPCs), the cells that have the capacity to recapitulate the tumor by transplantation (often referred to as cancer stem cells). Using an orthotopic transplantation assay for TPCs that my lab created, we showed that lung cancers of different genotype have TPCs with distinct markers (Curtis et al, Cell Stem Cell). This work identified the first bona fide lung TPC population, opening up many new opportunities to study the most crucial lung cancer cells to target for lung cancer therapy. More recently we have used our TPC assay to prospectively isolate metastatic lung cancer cells. We are currently identifying the molecular pathways crucial for metastatic TPCs.
Our current and future work will build on these discoveries to lead the field towards a better understanding of stem cell biology in the lung, development of innovative approaches for examining the cellular and molecular basis of lung disease and cancer, and identification of new avenues of therapy for pulmonary diseases.
The study of the relative contribution of genes and environment to the risk of common diseases presents a number of statistical challenges, from study design to analysis. My research focus is statistical methodology in genetic epidemiology, including family-based and population-based case-control studies.
My current projects include methods to measure association between haplotypes of multiple tightly-linked markers and disease in matched case-control studies and to detect gene x gene and gene x environment interactions. I am also interested in using joint variation in DNA sequence and gene expression to better understand disease etiology.
I collaborate with colleagues in the Department of Epidemiology and the Channing Laboratory on a number of large-scale cohort studies, such as the Nurses' Health Study, as well as the international Cohort Consortium for Breast and Prostate Cancer.
Abnormal regulation/degeneration of midbrain dopamine neuron is associated with major neurological and psychiatric disorders such as Parkinson’s disease, schizophrenia, and substance abuse. We are interested in understanding the molecular mechanisms underlying the development and maintenance of dopamine neurons in healthy and diseased brains. This is accomplished through detailed mechanistic studies of the relationship between critical extrinsic signals and intrinsic transcription factors, leading to important genetic networks and their functional roles in orchestrating the development and maintenance of dopamine neurons. Based on this molecular information, we seek to translate our results to preclinical and clinical application for neurodegenerative disorders such as Parkinson’s disease. In particular, we identified several key transcription factors that are crucial for early development and long-term maintenance and protection of midbrain dopamine neurons, leading us to identify them as potential drug targets for neurodegenerative disorders. We established efficient in vitro and in vivo assay systems and are currently investigating the development of novel therapeutics that may have neuroprotective and disease-modifying effects on neurodegenerative disorders.
Another area of research interest is the study of stem cells. In particular, we have recently focused on the development of clinically feasible and safe induced pluripotent stem (iPS) cell technology, which has great potential to study and treat human diseases. At present, the majority of iPS cells are derived through the use of viral vectors, resulting in clinically unsafe stem cells. We are interested in developing clinically and biomedically ideal iPS cells by safe techniques such as protein-based reprogramming with the long-term goal of advancing future personalized regenerative medicine. Once this technology is fully optimized, it will open an era of ‘cellular alchemy’ and provide potential platforms for human disease mechanism studies and novel therapeutic developments.
We are interested broadly in the use of genetic approaches to understand human disease. One major interest is the tumor suppressor gene syndrome tuberous sclerosis. We pursue studies on the human molecular genetics of this disease, develop mouse models using null and conditional alleles of TSC1 and TSC2, explore biochemical and signaling pathways, and explore therapeutic approaches. There is a particular interest in the generation of brain models of this disorder. A second major interest is lung cancer genetics. We are developing assays for the detection of clinically relevant mutations in lung cancer specimens, and are exploring the role of the TSC genes in lung cancer development.
Research approaches in common use in my lab include DNA variation detection, automated sequencing, generation of conventional and conditional mouse knock-outs, primary cell culture, protein analysis and immunoblotting, signaling pathway analysis, and high throughput genotyping. I am Director of the Brigham and Women's Hospital DNA Sequencing Core Facility, and Director of the Harvard Partners Center for Genetics and Genomics Genotyping Facility
Research in my laboratory focuses on developmental oncobiology of epithelial cancer. We are particularly interested in understanding how cancer stem cells evolve from normal target cells of cancer through accumulation of mutations and through interaction with microenvironments, as avenues for identifying pathways unique to them. We study this mainly through developing and analyzing novel mouse models of human cancer based on genetic events occurring in patients. Currently, we focus on modeling recurrent chromosomal abnormalities recently identified in increasing numbers of epithelial cancers (e.g., breast cancer, prostate cancer). The in vivo studies are complemented by cell culture based studies to decipher molecular mechanisms underlying tumor initiation and progression.
Xihong Lin is Professor of Biostatistics and Co-ordinating Director of Program in Quantitative Genomics of Harvard School of Public Health. My group's major research interests lie in development and application of statistical and computational methods for analysis of high-dimensional genomic and 'omics data in population and clinical sciences, and for analysis of correlatd data, such as longitudinal, clustered and spatial data.
We are interested in statistical genetics and genomics, genetic and epigenetic epidemiology, genes and environment and medical genomics. Current research projects include genome-wide association studies, next generation sequencing studies, gene-environment interactions, and genome-wide DNA methylation studies, pathway analysis and network analysis, proteomics.
* Statistical missing data problems, imputation methodology.
* Gibbs sampling and other MCMC methods, rate of convergence.
* Markov structure, graphical models (software BUGS), and genetics.
* Image reconstructions: PET, SPECT, etc.
* Bayesian methodology; Even Bill Gates talks about Bayesian ideas!!
* Nonparametric hierarchical models, model selections and testings.
* Large-scale computation and optimization, e.g., VLSI design; Dynamic systems; Computer vision.
* Monte Carlo filters, Sequential importance sampling and resampling.
Our goal is to provide state-of-the-art small animal imaging services to researchers in the Longwood Medical Area of Harvard Medical School. These services include multi-modality imaging, advanced data analysis, image fusion resources, and a satellite animal facility for longitudinal studies. A detailed description of our instruments and services are provided on our website, and we welcome questions and comments.
We utilize genetic engineering techniques in mice, in conjunction with electrophysiology, optogenetics, pharmacogenetics and rabies mapping, to elucidate central neurocircuits controlling feeding behavior, body weight homeostasis, and fuel metabolism. Specifically, transgenic, knockout, knockin, and cre-dependent AAV viral approaches (for delivery of optogenetic, DREADD and monosynaptic rabies reagents) are used to manipulate and map neuronal circuits. The goal of these studies is to link neurobiologic processes within defined sets of neurons with specific behaviors and physiologic responses. The ultimate goal is to mechanistically understand the “neurocircuit basis” for regulation of food intake, energy expenditure and glucose homeostasis. Given our expertise in gene knockout and transgenic technology, we can efficiently and rapidly create numerous lines of genetically engineered mice, important examples being neuron-specific ires-Cre knockin mice, which enable cre-dependent AAV technology. This allows us to bring novel, powerful approaches to bear on the neural circuits underlying behavior and metabolism. Our combined use of mouse genetic engineering, brain slice electrophysiology, and whole animal physiology is ideally suited to studying these problems.
Specific areas of interest include:
Neurobiological and neurocircuit basis for leptin action and melanocortin-4 receptor action, role of synaptic transmission and NMDAR-mediated synaptic plasticity within feeding circuits, afferent inputs regulating AgRP and POMC neurons, efferent circuits responsible for effects of AgRP and POMC neurons on feeding behavior, dissection of neural pathways regulating sympathetic outflow and energy expenditure, and finally neural mechanisms by which the brain controls glucose homeostasis.
The MGH Biomedical informatics Core (MGH BMIC) serves the information management and analysis needs of the MGH/Partners/Harvard research community as well as non-profit organizations and industry. MGH BMIC has expertise in biomedical informatics, and leverages re-usable tools developed by the group to offer services in a cost-effective manner.
The Biostatistics Center provides support to MGH investigators, as well as serving as a Coordinating Center for several NIH-supported projects. The Center's staff includes biostatisticians, physicians, research nurses, data managers, project managers, research assistants, and computing staff.
The MGH Center for Systems Biology (CSB) was established in 2007 as one of the five thematic interdisciplinary Centers at MGH. The Center is directed by Professor Ralph Weissleder, and is located on two floors in the new Simches Research Building. The mission of the Center is to analyze at a systems level how biological molecules, proteins and cells interact in both healthy and diseased states.
Through a multidisciplinary approach that combines clinical insight with powerful technologies, CSB faculty pursue systems-level research that is at once fundamental, and yet immediately linked to the diagnosis and treatment of human disease. While these approaches are generalizable to many diseases, the Center has particular strengths in complex human conditions such as cancer, cardiovascular disease, diabetes, autoimmune disease, and renal disease. This goal is enabled by particular faculty expertise in genomics, chemical biology, physiology, bioimaging, and nanotechnology.
The MGH Gordon PET Core provides investigators with required personnel, equipment, and services to design and conduct research studies using positron emission tomography.
The MGH Metabolic Imaging Core offers specialized imaging techniques including quantitative computed tomography (QCT), magnetic resonance (MR) spectroscopy of muscle and high-resolution MR imaging. These techniques are employed for studies evaluating body composition and metabolic disorders of muscle, bone, marrow, cartilage and liver. The Core also performs imaging for anatomic and structural studies in humans, phantoms and cadaveric specimens.
The core facilities at MGH Pathology provide flow cytometric cell sorting and analysis, image analysis and mass cytometry with the most sophisticated instruments currently available. There are two facility locations, one at MGH (Simches) and another at the Charlestown Navy Yard (CNY).
Flow Cytometry (Simches and CNY): The core is able to analyze and physically separate cells based upon features detectable with fluorescently labeled monoclonal antibodies. We are able to sort unfixed specimens in our BSL2+ FACSAria Fusions, at both our Simches/Boston and Charlestown Navy Yard locations.
Multispectral Imaging Flow Cytometry (Simches): The Amnis technology combines flow with fluorescent and bright field image based analysis.
Mass Cytometry (CNY): Helios, which is a CyTOF (cytometry by Time-Of-Flight) system, permits single-cell analysis using stable heavy metal-tagged antibodies (~35) rather than fluorescent moieties.
Welcome to the Magnetic Resonance Facility of the Department of Chemistry and Chemical Biology, Harvard University, in the Laukien-Purcell Instrumentation Center.
The ultimate goals of Joseph Majzoub's work are to understand how various stresses affect health.
The specific aims of the Majzoub laboratory's studies are to determine the impact of corticotropin releasing hormone (CRH) and vasopressin excess and deficiency on regulation of the neuroendocrine and behavioral responses to stress. The researchers seek to identify other neuropeptides related to CRH which may have similar functions. Because abnormal regulation of such neuropeptides likely contributes to disease, the molecules and their receptors are attractive targets for the development of new drugs.
Majzoub's work is also directed at determining how DNA variants in the gene for corticotropin releasing hormone affect stress and other behaviors, including appetite. He and his colleagues are currently working to define how transcriptional silencers interact with transciptional activators to regulate CRH gene expression
About Joseph Majzoub
Joseph Majzoub received his MD from Stanford University School of Medicine. He completed an internship and residency in Internal Medicine at Brigham and Women's Hospital and a fellowship in Adult Endocrinology at Massachusetts General Hospital.
He is the recipient of several teaching awards, including the A. Clifford Barger Award for Excellence in Mentoring from Harvard Medical School and the 2002 Irving M. London Teaching Award from Harvard Medical School-Massachusetts Institute of Technology Health Sciences Technology (HST) Program.
The Martinos Center's dual mission includes translational research and technology development. The core technologies being developed and used at the center are magnetic resonance imaging (MRI) and spectroscopy (MRS), magnetoencephalography (MEG) and electroencephalograpy (EEG), near infra-red spectroscopy (NIRS) and diffuse optical tomography (DOT), Positron Emission Tomography (PET), electrophysiology, molecular imaging, and computational image analysis. A particular area of innovation at the Center is Multimodal Functional Neuroimaging which involves the integration of imaging technologies. We are also world leaders in the development of primate neuroimaging techniques. Major areas of research at the center include, psychiatric, neurologic and neurovascular disorders, basic and cognitive neuroscience, cardiovascular disease, cancer and more. With an extensive and expanding inventory of state-of-the-art imaging facilities, a world class team of investigators and collaborators, and important government, industry and private supporters, the Martinos Center is leading the way to new advances and applications in biomedical imaging.
The mass spectrometry, proteomics, metabolomics and lipidomics facility at Beth Israel Deaconess Medical Center was established in 2004 led by Dr. John Asara and continues to grow rapidly with expanding multi-omics services. We provide excellent proteomics, metabolomics and lipidomics services with low prices and fast turnaround times. We have cutting edge instruments operated at optimal sensitivity and work and publish with world class researchers. We also maintain an active internal cancer proteomics and small molecule research program with collaborative efforts. Our expertise is in identifying and quantifying protein modifications and dynamic protein-protein interactions in addition to polar metabolomics profiling, flux analysis and lipidomics profiling. We accept collaborations from anywhere in the world and look forward to helping you and progressing your research to the next level.
The FAS Center for Systems Biology Mass Spectrometry and Proteomics Resource Laboratory provides mass spectrometry and strategic consulting in Proteomics and Small Molecule analysis for Life Science and Chemistry researchers as well as others worldwide. This resource brings together the state-of-the-art expertise and instrumentation of the Microchemistry and Proteomics, CCB Mass Spectrometry, and Bauer Center Core laboratories, leveraging our breadth of experience to provide the best possible support for your research.
MassGeneral Institute for Neurodegenerative Disease was founded in 2001 with a mission to translate laboratory discoveries into prevention, treatment and cures for Alzheimer’s, ALS, Huntington’s, Parkinson’s and other neurodegenerative diseases.
As a specialized research center funded by the United States Department of Health and Human Services, the Massachusetts Alzheimer's Disease Research Center welcome you to learn more about the extensive research, training and outreach programs that are offered, and we hope that you will join us in our efforts to discover effective treatments and an eventual cure for Alzheimer's disease.
Founded in 1824 by Drs. Edward Reynolds and John Jeffries as a one-room clinic to treat Boston's needy, the Massachusetts Eye and Ear Infirmary has earned an international reputation for its successful treatment of the most difficult diseases and conditions of the eye, ear, nose, throat, head and neck, and for its outstanding contributions to medical research and education.
Mass General has long been a leader in successfully bridging innovative science with state-of-the-art clinical medicine. With an annual research budget of more than $786 million, Mass General conducts the largest hospital-based research program in the United States - a program that spans more than 20 clinical departments and centers across the hospital. This funding drives discoveries and breakthroughs in basic and clinical research, which translate into new and better treatments that transform medical practice and patient care.
The Host-Microbiome Center supports studies evaluating contributions of the microbiota in health and disease. Core resources include:
(1) Gnotobiotic (germfree) animal facility with 60 isolators and 600 cage-containment system for SPF housing and short-term gnotobiotic or indefininte complex associations. The germfree core maintains common gnotobiotic stocks for experiments and assists investigators in setting up experimental systems and maintaining breeding colonies of dedicated lines.
(2) Microbiology Unit which provides microbiologic support for culture of aerobic and anaerobic species, biochemical characterizations, continuous chemostat/fermenter analyses, metabolite phenotyping of short chain fatty acids (SCFA), and has access to a large strain repository of human and animal commensal species and pathogens, including genetically tenable strains and systems developed by the unit.
(3) Molecular Unit which offers next generation sequencing (NGS) studies including 16S rRNA gene phylotyping, bacterial whole genome sequencing, and multiple qPCR/rtPCR analyses.
(4) Computational Unit which evaluates complex, longitudinal dynamics of the microbiota and maintains dedicated compute nodes in a HIPAA-compliant environment in the Partners ERIS compute cluster. Computational faculty have developed novel algorithmic approaches to study microbiota dynamics at the organismal and gene-level, and to incorporate host co-variates.
(5) CLIA (clinical laboratory) Unit, which provides clinical trials support for microbiome and other clinical studies and access to discarded clinical samples.
(6) Administrative Unit for assisting investigators with preparation of IRB and IACUC protocols, developing project quotes and providing project management support.
The Center is supported in part by a Massachusetts Life Sciences Center (MLSC) capital grant, and provides support to academic, non-profit and commercial groups within the state and beyond.
Massey conducts cancer research at every level, including basic science (laboratory), translational, clinical and population sciences research. A major strength for Massey is in facilitating the translation and real-world application of research discoveries into improved treatments and patient care and advances in cancer prevention and control.
A key part of the research cycle is developing and conducting clinical trials that test promising scientific breakthroughs, and Massey leads Virginia in offering one of the largest cancer clinical trials menus as well as a statewide clinical trials network that bring Massey’s cutting-edge trials to patients throughout the Commonwealth.
Massey is nationally recognized for its work in cancer disparities, studying the socioeconomic and cultural forces causing or contributing to disparities in cancer outcomes with a focus on minorities and the medically indigent.
McLean Hospital is a comprehensive psychiatric hospital committed to providing easy access to superior quality, cost-effective mental health services in the Boston area, Massachusetts and beyond. McLean Hospital is accredited by the The Joint Commission (TJC), licensed by the Massachusetts Department of Public Health (DPH), Massachusetts Department of Mental Health (DMH), and certified by the Centers for Medicare and Medicaid Services (CMS).
The McLean Hospital Animal Care Facility provides services to the research community at McLean mainly by ensuring adequate animal housing, animal care services and research environments. It is dedicated to consistently providing high customer satisfaction by rendering excellent service, quality care and an atmosphere conducive to accomplishing quality research. Being located in a psychiatric hospital, there is a unique opportunity for collaboration between research and clinical.
McLean Hospital is located at 115 Mill Street, in Belmont, Massachusetts. Research is conducted in multiple areas across campus including in Core holding facilities, at imaging locations and in satellite facilities. Having holding locations across campus allows the necessary research equipment to be accessible without the need to transport animals all the time through the Hospital.
Seven full time Animal Care Technicians are employed throughout the animal facilities located on the Hospital campus. They come from varying backgrounds and it is their responsibility to maintain a quality environment for the animals and monitor their health and well-being.
The McLean Hospital Microscopy Core Facility, located in the Mailman Research Center (MRC), is a shared user facility that supports basic scientific imaging and cell sorting research efforts within the McLean Hospital research community. Users from other Institutions are also welcome, with prior approval from the Core Director. Major instrumentation offered by the Core includes a JEOL JEM1200EX Transmission Electron Microscope (TEM), a recently acquired state-of-the-art Leica SP8-TCS Laser Scanning Confocal Microscope (LSCM), and a newly acquired Bio-Rad S3 Fluorescence Activated Cell Sorter (FACS).
The McLean Hospital Research Pharmacy provides a variety of medication related services to investigators throughout the course of their study. From initial protocol review through study closeout, we can assist as needed at any stage.
The McLean Imaging Center (MIC) Core provides Magnetic Resonance Imaging (MRI) services to Partners-affiliated and non Partners-affiliated researchers. The available facilities of the Core include several MR machines at different field strengths (3T, 4T and 9.4T), optical imaging equipment, sophisticated mechanical and electronic fabrication equipment, and an extremely powerful computational cluster.
The MIC is an academic, multidisciplinary center comprised of scientists with a diverse range of backgrounds and training, including neuroscience, pharmacology, physics, electrical engineering, psychology, psychiatry, and medicine. The wider hospital also provides rich resources for collaboration – MIC staff members have many collaborative projects in conjunction with the clinical departments throughout the hospital. Furthermore, the proximity of collaborators at numerous nearby universities and downtown hospitals provide a vast array of opportunities to study various patient populations and provide access to an extensive variety of specialized equipment.
The main objective of the Joslin's Media Core is to reduce the cost and labor of making tissue culture media and other reagents required by the Joslin investigators. By centralizing preparation of these reagents, the Core provides high quality reagents at a significantly reduced cost to the investigators. In addition, the Core provides services to overcome labor intensive reagent needs, like plate pouring services and preparation of specialized buffers and reagents for cell and molecular studies.
The Media Core makes and provides over 10 different mammalian tissue culture media to the Joslin investigators for their studies. In addition, the Core prepares and provides several buffers and solutions to the Joslin investigators. The core also makes a variety of broths and agars for growing bacterial cultures, and provides agar plates and plate pouring service to the investigators. Over the past five years (2006-2010), by preparing and providing over 6250 liters of media and 2850 agar plates per year to the Joslin investigators the Media Core serves an important function in the efforts of these investigator to find cure for diabetes and its complications.
The Medical Research Group (MRG) is involved in collaborative clinical research studies and committed to the development of superlative research at Brigham and Women’s Hospital and Brigham and Women’s Faulkner Hospital.
The Medical Research Group conducts clinical research studies and has extensive experience in the design, implementation and coordination of sponsored human research. The MRG investigators are involved in basic and clinical research in human subjects.
Areas of interest of the MRG include Cardiovascular, Diabetes and Hypertension. The investigative efforts in these areas are paramount to the advancement of prevention, diagnosis and treatment of disease in patient populations.
The Megason lab is interested in how the program contained in the genome is executed during development to turn an egg into an embryo. To this end we have initiated the Digital Fish project. In the Digital Fish project, we are using several technologies we developed including in toto imaging, GoFigure, and FlipTraps to "watch" the execution of circuits in living zebrafish embryos during development in a systematic fashion.
We study the developmental biology of the pancreas with a view to finding new treatments for diabetes. Our aim is to understand how the pancreas develops and use that information to grow and develop new pancreatic cells (Islets of Langerhans). This project is an example of the larger question of how vertebrates make an organ from undifferentiated embryonic cells.
Our experimental approaches use the tools of molecular, cellular and chemical biology to investigate how precursor or stem cells give rise to the pancreas and how pancreatic tissue is maintained in adults. This includes identifying cells and gene products that specify developmental fates and physiological functions during organogenesis, regeneration, and following autoimmune attack. We use a variety of techniques including functional genomics, chemical screening, tissue explants and grafting. While we use several vertebrate organisms, including frogs, chickens, and axolotls, the main thrust of our work is done with human stem cells, both embryonic and iPS cells, as well as their mouse counterparts.
Directing cells to form new pancreatic tissue has a practical significance: if our studies are successful, it should be possible to apply our conclusions to human cells and provide a source of insulin-producing beta-cells for diabetics.
The Microarray Core provides services for genome-wide analysis of gene expression, nucleotide variation, copy number variation, and chromatin protein binding sites. The core platforms include microarrays and "next generation" sequencing. Consultation on experimental design, and assistance with data analysis are also available.
The Microarray Core carries out gene expression profiling on 3' arrays and on Exon arrays; genotyping and comparative genomic hybridization both on single nucleotide polymorphism (SNP) arrays, and Chromatin ImmunoPrecipitation localization (ChIP-on-Chip). All services use oligonucleotide microarrays. Biostatistical support to assist in analyzing the data is available. The services of the Core are accessible to DFCI investigators and to investigators outside of DFCI.
This is a user-run core that features a Bruker MALDI-TOF MS Biotyper and associated software for the identification of microorganisms. The primary use case for our core is the identification of a set of unknown bacterial or fungal strains from a pure colony on a culture dish.
Equipment access: These machines are primarily for use by Harvard-NIEHS Center Core members. Center members will be prioritized. All new users must be trained by the appropriate facility manager and be approved to use the equipment in the facility. Users will be charged a fee for this training. All users must obtain the financial approval from their PI and financial manager. Please submit a PO number or the Harvard billing code prior to the first use of the facility.
The Molecular Biology Core Facilities (MBCF) was created in 1986 to allow investigators at the Dana-Farber Cancer Institute access to cutting edge molecular biology tools which would be tested and developed in a shared setting. Collaborations can be set up with anyone in the world. Although these services are primarily focused on cancer and AIDS research, there is a broad spectrum of research that uses these resources.
The MCIF mission is to advance therapeutic and diagnostic research through radiotracer development for research investigators. MCIF helps investigators quickly move discovery-stage concepts to in-vivo models, generating data to support grant applications, publications, and drug development efforts.
The molecular electron microscopy facility at Harvard Medical School is predominantly used for our own research and can therefore not be considered a service facility. We are, however, committed to make our technology available to as many research groups in the community as possible. If you are interested to use molecular electron microscopy, please contact us by phone or email.
The Molecular Genetics Core Facility (MGCF) is a non-profit core laboratory in the Program in Genomics and Genetics Division of Children's Hospital Boston offering genomics services for academic research institutions. The majority of MGCF users are investigators from Children's Hospital Boston and the surrounding Harvard affiliates, but the MGCF also serves laboratories throughout the entire United States. The MGCF is comprised of a compilation of smaller cores partially supported by private and federal funds. Funding is provided in part through The Intellectual and Developmental Disabilities Research Center, The Manton Center for Orphan Disease Research, The Wellstone Center for Muscular Dystrophy, and The Neuromuscular Disease Project of the Program in Genomics at Children's Hospital Boston.
The overall objective of the MGCF is to provide a location where researchers can have access to high quality, low cost genomic technology services and expertise in a timely, affordable manner. The services offered include DNA sequencing, Next-Gen sequencing, Affymetrix and Illumina whole-genome expression and genotyping microarray technology, microsatellite genotyping, and high-throughput qPCR and SNP services on the Fluidigm Biomark System. The MGCF also assists investigators with project design and collaborates on linkage and association study analysis.
The core is equipped with the following instruments: Illumina MiSeq Next Generation Sequencer, Arcturus XT Laser Capture Microdissection System, Agilent 4200 TapeStation Bioanalyzer, Covaris E220 Ultra-Sonicator, ABI 7000 and 7500 Fast Real-Time qPCR systems, Li-Cor Odyssey System Infrared Imager.
On an hourly fee basis we provide: training on equipment usage, consultations, core setup, data analysis, troubleshooting, primer design, LCM usage. On per sample or per run fee basis we provide: qRT-PCR runs, quality and quantity DNA and RNA analysis, Covaris ultrasonicator sample shearing, LiCor scanning.
For details contact Dr. Petkova.
The Molecular Pathology Core Laboratory (MPCL) works to advance molecular pathology-based cancer research. The group addresses significant scientific and clinical research needs and has created a central hub where researchers can interact, collaborate, and utilize novel molecular pathology technologies to translate basic science discoveries into patient care applications for cancer. Our mission comprises comprehensive pathology annotation to encompass clinical, morphological, and molecular characteristics, genetic discovery in primary human tumors, with limited material and in real time, novel biomarker identification and pre-clinical trials, and transitioning assays to the clinical setting
The objective of the Molecular Phenotyping and Genotyping Core is to support investigators in the study of molecular mechanisms of disease by providing equipment, expertise, and services in molecular phenotyping, including nucleic acid sequence analyses, gene expression, and other "-omics" analyses, which would be too specialized or costly for individual laboratories to perform independently. Formerly known as the Advanced Genomics and Genetics Core, the Molecular Phenotyping Core is newly-named in recognition of the expansion of its analytical capacities to reflect not only genetic and genomic analyses but also metabolic phenotyping.
The Molecular and Cellular Biochemistry Core is dedicated to providing HDDC investigators and their trainees with access to a variety of methods to determine the compositions of tissues, as well as their cellular and subcellular specimens. The Core Scientists offer a broad range of analyses and preparatory services including Proteomics. Importantly, the Core also provides training in the application of state-of-the-art techniques in molecular analysis of proteins, lipids and nucleic acids. The main Core laboratory is located at Brigham and Women’s Hospital (BWH) and the satellite Core laboratory is located at Children’s Hospital
We perform a broad array of biochemical and analytical assays that are not typically available within laboratories of HDDC members. These have generally been adapted so that they may be performed in large numbers on microplates. These include quantification of lipids, mRNA and protein and a full array of mass
spectroscopy services for protein analysis (and soon to be expanded for lipidomics). We also offer both analytical and preparatory separations by a variety of methods.
Mount Auburn Hospital is a vibrant regional teaching hospital closely affiliated with the Harvard Medical School. Our caregivers have been valued members of the community for well over a century.
The Mouse Behavior Core (MBC) is a state-of-the-art research facility established by Harvard Medical School (HMS), in collaboration with Brigham and Women’s Hospital (BWH). The MBC is available to all members of the research community.
The goal of the MBC is to provide the highest quality of behavioral assessment in mice to the research community.
The MBC is outfitted with multiple rooms of equipment for behavioral testing in mice. Available assays include models of anxiety, depression, learning and memory, attention, social interaction, motor activity and coordination, and a 24 hr/day system that monitors locomotor activity, food intake, and metabolic measures. The surgical suite is outfitted with two stereotaxic frames. Housing is available in an adjacent vivarium.
The Mouse Imaging Program (MIP) at the Center for Systems Biology is a uniquely integrated imaging resource providing the larger Harvard/MIT research community with access to state-of-the-art in vivo imaging technologies. The program offers magnetic resonance imaging (MRI), positron emission tomography (PET-CT), single photon emission computed tomography (SPECT-CT), computed tomography (CT), bioluminescence (BLI), fluorescence mediated tomography (FMT), and various other fluorescence imaging technologies. The fully integrated program also provides mouse holding facilities for serial imaging, surgery, anesthesia and veterinary care. Image reconstruction, 3D display, fusion, quantitative image analysis and online data access are also available. The program performs its own research, aimed at continuously improving existing imaging technologies and has deep knowledge of cardiovascular, oncology and neurological mouse models of disease. A list of publications made possible by utilizing MIP resources is available on the Program web site. Imaging requests may be submitted through the MIP website.
Multi-Gene Transcriptional Profiling (MGTP) is a real-time PCR based technique, developed in our lab, for quantifying mRNA copy numbers per cell with high reproducibility and accuracy.
Primary Goals of the MGTP Core:
* To make MGTP services available to investigators, and assist them in advancing their research and obtaining grants;
* To assist studies of molecular signaling mechanisms and pathways, discovery of biomarkers, and development of clinical assays; and
* To share the resources of our primer library, which currently includes about 2400 pre-validated human, and mouse genes.
The MGTP Core makes these unique and powerful capabilities available to biomedical researchers. Thousands of pre-validated primers are available for use, and others can be designed on demand.
The National Biodiversity Institute (INBio) of Costa Rica is a private research and biodiversity management center, established in 1989 to support efforts to gather knowledge on the country's biological diversity and promote its sustainable use. The institute works under the premise that the best way to conserve biodiversity is to study it, value it, and utilize the opportunities it offers to improve the quality of life of human beings.
INBio is a non-governmental, non-profit, public interest organization of civil society that works in close collaboration with different government institutions, universities, the private sector and other public and private organizations, both within and outside Costa Rica.
The Neurobiology Imaging Facility is the Neurobiology Department core facility for light microscopy.
Our mission is to advance research by providing services in optical imaging, introducing new optical imaging equipment, providing learning opportunities to researchers in the Longwood area and increasing the general imaging expertise of neuroscientists.
The Neurodevelopmental Behavior Core (NBC) was designed to provide a time-efficient and cost-effective service for the comprehensive characterization of complex behaviors in mouse models of neurodevelopmental disorders, and for testing novel therapeutic drugs and interventions in mouse models of these human disorders. The NBC provides the necessary equipment, protocols and technical support for studying neurodevelopmental disorders, focusing not just on “snapshots” but changes in developmental milestones over time. The Core is equipped to perform extensive batteries of behavior tests that phenotype specific social, emotional and cognitive behaviors, as well as motor, auditory and visual function, together with measures of the general health of the animals. This behavior facility also provides a unique opportunity for training fellows, graduate and undergraduate students as well as PIs.
The NBC is available for use by BCH and non-BCH scientists.
The NextGen Core is a collaboration between the Department of Molecular Biology, the Center for Human Genetics Research, the Center for Computational Biology, and the Executive Committee on Research (ECOR).
Currently, the Core operates using a single Ilumina HiSeq instrument, accompanied by Illumina's cBot for cluster generation. This upgrade from our Genome Analyzer II doubled our capacity and greatly increased the data amount, quality, and stability over extra-long reads.
The Core is located in the state-of-the-art Richard Simches Research Center on Cambridge St. as part of the MGH main campus in Boston. The many multi-investigator groups in the building - including those that study human genetics, stem cells, genomics, and more - make it the perfect location for the Core to service the researchers in those groups. The majority of customers come from MGH, but we also service customers at other academic medical centers and industry.
The mission of the NIC@HMS is to: enhance basic research by providing access to state-of-the-art microscopy and imaging equipment, provide training courses on basic and advanced light microscopy techniques for the benefit of HMS and the greater Boston research community, introduce the latest innovations in light microscopy and imaging to the HMS community, serve as a learning center for our corporate partners and contributions, and provide a dedicated NIC@HMS director for ongoing technical consultation and support.
Nuclear Medicine and Molecular Imaging performs non-invasive, painless imaging tests that can reveal important information about your child's health.
Nuclear medicine uses short-lived radiopharmaceuticals and specialized cameras to create images of the human body. The images show blood flow and functional and metabolic activity within organs and lesions. This technology allows early diagnosis and monitoring of disease and can often make invasive procedures unnecessary. It also complements information obtained from X-rays, computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI). Some applications of nuclear medicine are used for treatment of certain specific diseases.
The Nutritional Biomarker Laboratory at the Harvard T.H. Chan School of Public Health has more than 30 years of expertise in the analysis of antioxidants and fatty acids in blood, tissues, and foods backed by external quality monitoring programs administered by the National Institute of Standards and Technology (NIST), the American Oil Chemists’ Society (AOCS), and the Centers for Disease Control and Prevention (CDC). More recently we have added a blood lipid panel, 25-OH vitamin D EIA assay, tyrosol and hydroxytyrosol in urine and plasma, and various ELISA-based assays. We are skilled at the development of new assays that are amenable to our instruments and are happy to discuss projects beyond the scope of our standard panels.
The Office of Technology Transfer is responsible for the identification and protection of new inventions and other commercially-valuable intellectual property that arises from Joslin's research and clinical activities. The Office handles, or assists with, contracts and other research-related interactions between Joslin staff and industry.
Probing skeletal diseases. Human beings are 60% water; so what keeps us from slipping off our bones and into a puddle on the floor? The short answer is collagen, a chainlike molecule that helps prevent joints from pulling apart and teeth from getting loose. Breakdowns in the formation and organization of collagen cause a number of diseases, including osteoarthritis. The Olsen lab is trying to identify and sequence the genes that help to create different types of collagen. Mice that are missing the gene for one type, collagen IX, seem predisposed to suffer from a disease much like human osteoarthritis. This exciting indication of a genetic cause of arthritis, which the lab is investigating further, creates an even stronger motivation to learn the genetic basis for diseases involving other types of collagen and other proteins in the extracellular matrix that surrounds and connects cells. In addition, the lab is identifying gene mutations that are responsible for defects in skeletal patterns in developing limbs and growth of bones during development. In a recent discovery the inherited disorder synpolydactyly, a condition characterized by extra fingers and variable fusion of fingers, was found to be caused by mutations in a gene, HOXD13, that controls the activity of many other genes which are important for cell growth and differentiation during limb development. Cleidocranial dysplasia, a condition characterized by delayed suture ossification in the skull, supernumerary teeth and missing clavicles, was found to be caused by mutations in the gene CBFA1, a transcription factor needed for cells to become bone cells.
Probing vascular disorders. Blood vessels are tubes of endothelial cells surrounded by layers of smooth muscle cells and connective tissue proteins. During development this complex structure forms as a result of biochemical signals between endothelial cells and smooth muscle cells. Sometimes this biochemical communication fails and abnormal blood vessels form. By analyzing gene mutations causing such vascular abnormalities, much can be learned about the signals that are necessary for normal blood vessel development. In addition, identification of genes responsible for inherited vascular malformations provides a basis for development of rational therapies in the clinical treatment of vascular disorders. One by one, the Olsen lab is trying to identify the genes that cause several forms of venous malformations and determine the precise mutations in these genes.
Confocal and multiphoton are modern fluorescence techniques in microscopy for generating optical sections from live or fixed biological specimens. In general, both techniques employ a point scanning and point detecting design. The confocal microscope achieves point detection by using a confocal pinhole to block off out-of-focus emission from the specimen. The multiphoton microscope, on the other hand, generates intrinsic point emission directly from the in-focus spot, thereby eliminating the need for a confocal pinhole. Subsequent scanning of the entire field of view results in an optical section. Computer reconstruction of serial optical sections, collected at consecutive axial (z) positions, can reveal the spatial localization of cells and tissues (sometime subcellular molecules) in 3D. The ability to see biochemical processes in live cells, in real time, sheds light on the vastly complex molecular world of cells and may allow IDI scientists to identify new targets for drugs that will treat exposure to dangerous toxins and bacteria as well as fight a wide variety of diseases.
The Organic Chemicals Service fosters research collaboration among Center members in the area of exposure biology by providing analytical tools and expertise needed to investigate organic compounds in environmental and occupational epidemiological research.
The goal of the Orkin laboratory is to understand how commitment to specific blood lineages is programmed and how cell-specific patterns of gene expression are established. Since gene expression is controlled by nuclear regulatory factors (transcription factors), efforts have centered on identifying those crucial for development of stem cells or individual lineages. Research encompasses conventional molecular biology and contemporary mouse genetics.
The PCPGM Bioinformatics Core recognizes that quantitative analytic methods are now central to the pursuit of biomedical research. Activities of the Bioinformatics Core range from the provision of "Services" to fully-collaborative grant-funded investigations.
The Partners Biorepository for Medical Discovery (PBMD), operated by the Partners HealthCare Center for Personalized Genetic Medicine, aims to foster collaborations among investigators, physicians and patients seen at Partners HealthCare institutions. This Partners-wide project is at the forefront of developing the tools needed to expedite the discovery and introduction of new ways to fight disease.
As we advance the age of personalized medicine, it is critical that physicians and scientists work with large numbers of patients to advance the delivery of healthcare. The Biorepository provides an opportunity for patients to interact with investigative studies – safely, securely and privately – in ways that could have an enormous benefit for us all.
The Biorepository continues in a development phase, and is actively working with a number of groups at BWH and MGH who are consenting patients for clinical and translational research studies. Samples are maintained in an institution-wide repository which is a growing resource available to Partners investigators and research groups.
The BioSample Services Facility (BSF) provides sample handling and preparation resources to investigators in the Partners research community. Our goal is to efficiently and effectively process specimens enabling the generation of high quality data via down stream processes.
All projects containing subject samples and submitted to the BSF for handling must be IRB approved in advance. All specimens must be entered into our Laboratory Information Management System (GIGPAD) prior to delivery to the BSF.
Our staff will work with you to design an implementation plan that would best fit your research needs.
The DNA Sequencing Group at the Partners HealthCare Center for Personalized Genetic Medicine has a strong history of producing high quality, dependable, and informative results for collaborators and clients. The DNA Sequencing Group participated in the Human Genome Project, building the STS-Based BAC map for Human Chromosome 12, and providing Chromosome 12 tiling path clones to the Baylor Human Genome Sequencing Center for sequencing.
The group sequenced 113 BACs for the Mouse Genome Project, contributing 24 megabases of finished mouse sequences to the published Mouse Genome, as well as providing draft sequences for unique strains of several bacterial genomes, including Pseudomonas aeruginosa, and Vibrio cholerae. More recently, the group participated in identifying mutations linked to numerous diseases, either in collaborations or by providing client laboratories with full service resequencing and analysis.
"The Partners Genotyping Facility, part of the Partners HealthCare Center for Personalized Genetic Medicine (PCPGM), provides flexible, high quality, high-throughput SNP genotyping to the Harvard-Partners research community, including Harvard Medical School, hospitals in the Partners HealthCare network, investigators in the Dana-Farber-/ Harvard Cancer Center, and the Harvard School of Public Health. The portfolio of Genotyping methods at PCPGM now includes Illumina, TaqMan and TaqMan OpenArrays."
Note: DF/HCC members will receive the DF/HCC discount on both genotyping and sequencing services from our facility
The Microscopy Core of the Program in Membrane Biology (PMB) at MGH is equipped and staffed to provide a wide range of services to investigators from MGH and the Boston area scientific community in the area of light and electron microscopy. The Core is housed on the 8th floor of the Simches Research Center at MGH, and is directed by Dr. Dennis Brown, Ph.D. The Core will provide services ranging from complete performance of the technical procedures required, to full training of personnel. Among the techniques available are laser scanning confocal microscopy, spinning disk confocal microscopy, tissue fixation, sectioning, immunostaining and conventional immunofluorescence microscopy, image analysis, and all aspects of electron microscopy including immunogold staining. The Core facility provides a unique and important resource for members of the scientific community as they approach a variety of research problems that call for these advanced microscopy techniques.
Thus, the Microscopy Core has a variety of menus to fit the microscopy and immunocytochemistry needs of most PIs. Interaction usually involves a preliminary discussion with the Core director and/or other Core staff who will be involved in the work. Intellectual and practical input are then tailored to fit individual requirements.
The purpose of Pancreatic Islet Isolation Core of Boston Area Diabetes Endocrinology Research Center (BADRC) is to provide high quality islets to the local diabetes research community. The laboratory is physically located at The Massachusetts General Hospital (MGH). It is a specialized services facility (per OMB Circular A-21) and the only lab in New England produces human pancreatic islets under current Good Manufacture Procedure (cGMP) standards. The manufacturing facility supports the MGH clinic islet transplant program, a member of the Consortium of Islet Transplantation (CIT) which is working to advance clinical islet transplantation from an experimental trial to a standard care procedure.
Since its inception in 2008, the MGH Pancreatic Islet Isolation Laboratory has processed more than 160 human pancreata the majority of which generated islets that were distributed to investigators across the US for use in basic research. In 2011, we expanded our program to provide autologous human islet isolation to patients undergoing total pancreatectomy for chronic pancreatitis that has not responded to conventional intervention. This processing service has been offered to outside institutions and to date, approximately 30 patients from Mass General, Brigham and Women’s Hospital and Dartmouth-Hitchcock Medical Center of Dartmouth Medical School have benefited from this innovative technology.
We have conducted a variety of experimental studies on pancreatic islet transplantation in primate, porcine and rodent models. We also collaborate with researchers nationally to provide high quality nonhuman primate (NHP) islets for research. Our extensive experience in areas such as tolerance induction, encapsulation of islets, large/small animal surgery, islet isolation, and animal care allow us to be an ideal resource center for related studies.
Partners HealthCare Personalized Medicine (formerly known as the Partners HealthCare Center for Personalized Genetic Medicine or PCPGM) is a division of Partners HealthCare, an integrated health care system founded by Brigham and Women’s and Massachusetts General Hospital, both Harvard-affiliated teaching hospitals, and the largest independent hospital recipients of National Institute of Health (NIH) research funding in the United States.
Partners Personalized Medicine was founded in 2001 by Partners HealthCare and Harvard Medical School (HMS) as the Harvard-Partners Center for Genetics and Genomics. The center was launched before completion of the Human Genome Project as an early commitment to, and in recognition of, the potential for genomic knowledge to dramatically improve health care. This mission, to better understand and harness the unique genetic and genomic makeup of individuals to improve their health, continues today.
As a part of the Partners HealthCare system, and through its affiliation with Harvard Medical School, Partners Personalized Medicine is uniquely positioned to leverage the talent and resources of Partners HealthCare system and impact the research and clinical activities of one of the largest and most transformative health care systems in the country.
The Partners Research Computing Core was created by Enterprise Research Infrastructure & Services (ERIS) to offer dedicated services, consultation, and support within the teaching hospitals. Please check the service catalog as new services are added, or contact us if you need a consultation. Initial discussion is at no charge.
Research Ventures & Licensing (RVL) is a division of Partners HealthCare that coordinates commercialization services across Partners HealthCare, Brigham and Women’s Hospital and Massachusetts General Hospital. RVL offers support in the identification and protection of new inventions, the development of commercialization strategies, licensing, relationships with industry and the development of start-up companies. The RVL team has backgrounds in technology licensing, patenting, bench research, finance, funding, business, law and venture capital. Investigators are assigned to Research and Licensing representatives based on their departments and projects.
1. Manage inventions arising from research
2. Protect intellectual property
3. Determine commercialization pathway
4. Find industry partners and licensees
5. Identify technology funding options
6. Create marketing plans
7. Support PHS academic-industry alliances
Partners HealthCare, MGH and BWH employees and investigators are covered by the Intellectual Property Policy for Partners-Affiliate Hospitals and Institutions. The purpose of this policy is to promote the mission of Partners HealthCare Hospitals by making inventions, copyrightable works, and other intellectual property created by physicians, researchers, and trainees available for the benefit of the public while also providing a fair allocation of the financial costs and rewards associated with them.
Investigators who have additional questions about Intellectual Property, Commercialization or working with RVL should consult the RVL website at rvl.partners.org, or contact us directly.
This Tissue and Blood Repository Core provides specimen acquisition, processing and storage services, and access to archived frozen tissue specimens to the BWH/MGH/DFCI research community.
The Pathology Specimen Locator Core was established in 2008 and offers services that enable investigators with appropriate IRB approval to access tissues with fewer barriers. This is achieved through a web-based, integrated network of distributed searchable databases that contain de-identified, coded, pathologic information on post-diagnostic, excess paraffin-embedded tissues human materials.
Access to annotated human tissues with cancer is critical for translational research, which provides an increasingly important bridge between basic scientific research and clinical medicine. In a complex multi-institutional environment like the DF/HCC, the Core streamlines the process of tissue acquisition, provides a single point of entry for tissue-related services, and connects the necessary pathology expertise with bench scientists. The Core allows more investigators to gain prompt access to tissues, while ensuring that the tissues used in research have the pathology validation, a feature that is critical for any study involving the use of tissues.
The Ashton Award for Student Research is made possible by the generosity of Professor Peter Ashton and his wife Mary Ashton through the Peter and Mary Ashton Training Fund.
Our research group specializes in research related to the study of kidney function in various populations.
Assays for Study of Kidney Function
Our lab offers two renal function assays for measurement of renal plasma flow (RPF) and glomerular filtration rate (GFR) to analyze human kidney function.
• The RPF assay measures the clearance of para-aminohippurate (PAH)
• The GFR assay measures clearance of Inulin
• Sample pickup and storage is also available for study groups
Other Clinical Specialties
Our lab conducts clinical research with a specific focus on diabetes, hypertension, nephrology and the renin-angiotensin system (RAS) and cardiovascular disease. The assay services would be helpful to clinical researchers involved in these fields.
PAH plasma clearance provides accurate measure of RPF and requires placement of two IV’s in the patients arms—one in each arm. In one of these IV’s, PAH is infused at a rate dependent on the research participants current weight. The infusion continues for a period of time as specified in a study protocol. At certain specified time points, blood samples are obtained from the second IV. These blood samples are processed and the remaining sample is the plasma. This is retrieved by our lab and stored at 20°C until it is assayed. This process is the same for the Inulin assay for measurement of GFR. To measure Inulin clearance, plasma samples have to be hydrolyzed to a dialyzable product in a dilute hydrochloric acid solution without precipitating plasma proteins. Inulin clearance has become the standard method in determining GFR.
Certain study groups may wish to measure both RPF and GFR. In this circumstance, both PAH and Inulin can be infused together.
We have extensive experience in clinical research study design and sponsor funded research. If you have any questions about these topics please contact the personnel listed below.
The Preclinical Discovery Core (PDC) provides the infrastructural and consultative support for non-invasive measurements of alterations in body composition, muscle performance, physical function and metabolic performance to facilitate longitudinal studies of FPTs during aging and metabolic stress. The PDC is also continuing its mission to spearhead innovation- development of novel 7Tesla MRI techniques to provide mechanistic insights into FPT interventions.
The Preclinical MRI Core Facility at the Beth Israel Deaconess Medical Center offers instrumentation and expertise for a broad range of magnetic resonance imaging and spectroscopy applications for small animals, excised tissue and cell culture studies. We provide fee for service within BIDMC and to outside investigators.
Our research focuses on the development of statistical methods for uncovering the genetic basis of human disease, and on the population genetics underlying these methods.
The Program in Cellular and Molecular Medicine (PCMM), previously known as the Immune Disease Institute (IDI), is a research program at Boston Children's Hospital (BCH) recognized worldwide for its discoveries that increase the body's ability to fight disease and to heal.
The breakthroughs of PCMM scientists are greatly increasing our understanding of the influence of immune defense and inflammation on medical discovery, healthcare, and disease management.
PCMM officially joined seven other interdisciplinary programs at Children's Hospital in October 2012 with the goal of increasing collaborations and scientific synergies.
We are academically affiliated with Harvard Medical School (HMS), and our investigators hold appointments in departments of the medical school.
The Proteomics Center at Children's Hospital Boston offers the most up-to-date proteomics equipment currently available. This includes the latest equipment for protein separation and several state-of-the-art mass spectrometers, which detect and quantify proteins in a sample and measure them to determine their structure and characteristics.
The mission of PNGU is to identify and characterize the genetic basis of psychiatric, behavioral, and neurodevelopmental disorders and to translate these discoveries to improvements in clinical care and public health.
Psychiatric and neurodevelopmental disorders are common, costly, and often disabling conditions that affect individuals across the lifespan. Disability associated with neuropsychiatric disorders exceeds that of other medical illnesses, and psychiatric disorders are also associated with premature mortality. Familial and genetic factors are the best-substantiated risk factors for a broad range of neuropsychiatric disorders. Identifying and characterizing the genetic basis of these disorders offers hope for improving treatment and prevention strategies.
The PNGU Core Lab provides a variety of services intended to facilitate the identification and characterization of the genetic basis of psychiatric, behavioral, and neurodevelopment disorders as well as other complex disorders.
Services include assistance with study design and start-up, custom genotyping (SNP, other), DNA extraction and quantification, and sample preparation, tracking, and storage.
The PNGU Core Lab is open to both internal (MGH) and external investigators.
The Katharine H. Putnam Fellowships in Plant Science are made possible by the generosity of George and Nancy Putnam through the Putnam Fellows Fund. The Arnold Arboretum of Harvard University is an Affirmative Action/Equal Opportunity Employer and requires pre-employment reference and background screening.
The radiopharmaceutical chemistry research program occupies two research laboratories in the Enders research building at Children's: a radiopharmaceutical chemistry laboratory and a "hot" laboratory. A separate cell-culture laboratory is also available.
The radiopharmaceutical chemistry laboratory contains four fume hoods, approximately 50 linear feet of bench space, and is set up to accommodate three postdoctoral researchers.
The Biostatistics Core serves the needs of the HIV/AIDS researchers within the Ragon Institute and its affiliates. In particular, members of the Biostatistics Core provide expertise in the planning, conduct and analysis of research with the goal of enhancing the scientific quality of HIV-related research at the institute.
The primary objective of the core is to ensure that studies are well designed, correctly analyzed, clearly presented, and correctly interpreted.
The mission of the Ragon Institute Imaging Core is to bring the latest imaging modalities to bear on fundamental molecular and cell biological questions pertaining to infectious diseases. As an MGH core, it also serves the greater MGH community in all aspects of microscopy, flow cytometry and cell sorting. The Flow Cytometry division of the Ragon Institute Imaging Core is located on the 9th floor of 400 Technology Square in Cambridge. The core offers training, assistance and access to flow cytometers and other instrumentation. Consultation is provided on experimental design. Our high speed cell sorter is situated in a BL2+ facility, permitting sorting of fixed or live samples with up to BL2+ level of biosafety.
Since the Ragon Institute is also a collaboration between MGH, Harvard, and MIT, so too does the facility welcome members of the MIT and Harvard communities.
The mission of Ragon Institute Imaging Core, Microscopy Division is to bring the latest imaging modalities and technology to bear on fundamental molecular and cell biological questions pertaining to infectious diseases. As an MGH Core Facility, the Ragon Institute Imaging Core also serves the MGH greater MGH community. Since the Ragon Institute is also a collaboration between MGH, Harvard, and MIT, so too does the facility welcome members of the MIT and Harvard communities as we are now located in Cambridge at MIT.
The facility encompasses five imaging systems, including a Zeiss LSM510 laser scanning confocal microscope and a fully automated Zeiss Axio Observer microscope, both housed in BL2+ compliant facilities. These imaging systems are therefore fully equipped for both fixed and live cell imaging. In addition, the facility has two slide scanning systems (MIRAX MIDI and TissueFAXS) for high speed automated imaging and cellular screening of tissue sections and cultured cells on glass slides. In the Flow Cytometry section of the Imaging Core, we also have an ImageStream X Mark II by Amnis.
The core also serves as a resource for addressing a variety of imaging needs including consultation on a topics related to imaging applications, experimental design, and sample preparation.
The Reich laboratory studies Population Genetics & Medical Genetics.
Neutrophils and Pulmonary Infection
The Remold-O’Donnell Laboratory studies the role of SerpinB1 in protecting the host defenses of the lung against microbial infection. SerpinB1 (also called MNEI) is an ancestral and highly conserved serine protease inhibitor and a highly efficient inhibitor of neutrophil proteases. Our studies include work with patient specimens (cystic fibrosis, chronic lung disease of infancy) as well as microbial infection of animal models. We have shown that SerpinB1-/- mice are susceptible to bacterial lung infection with Pseudomonas aeruginosa. On infection with sublethal dose, SerpinB1-/- mice fail to clear infection. This defect is accompanied by an increased inflammatory response and by destruction of innate immune defense molecules in the lung including surfactant protein-D (SP-D). The recruited neutrophils also have a survival defect, accumulating as late apoptotic/necrotic cells and releasing proteases. Current studies are addressing the role of SerpinB1 and neutrophil proteases in lung infection with influenza virus, a highly important pathogen. The contribution of protective molecules such as SP-D that are targeted by neutrophil proteases are being examined through the use of transgenic mice. The role of SerpinB1 in neutrophil generation and neutrophil survival in steady state and in models of lung inflammation is being examined.
Platelet and T cell Defects in Wiskott-Aldrich syndrome
Our lab performs platelet studies based on the hypothesis that platelets from patients with Wiskott-Aldrich syndrome (WAS) are specifically defective in activation processes that depend on integrin “outside in” signaling. On treatment with agonists, the major platelet integrin αIIbβ3 is conformationally activated allowing binding to extracellular matrix. Bound ligand transduces signals across the membrane (integrin “outside-in” signaling) that activate the WAS protein (WASP), localized in platelets in the membrane skeleton. Active WASP generates new actin filaments responsible for altering platelet morphology as occurs when platelets spread on matrices or bind and aggregate at the blood vessel wall. The role of WASP in integrin outside-in alteration of cell morphology is thought to be important in stabilizing platelet aggregates and regulating platelet conversion to the procoagulant phenotype.
Research Computing (RC) facilitates the advancement of complex research by providing leading edge computing services across the Faculty of Arts & Sciences (FAS). RC staff maintain expertise in constantly changing computing technologies, while 'speaking the language' of the FAS researchers, to help them use computing more effectively.
Research Imaging is a key component of Boston Children’s Hospital’s ongoing endeavors in advancements of pediatric medicine, and is supported by the Department of Radiology. As a leading innovator in pediatric research imaging, we are at the forefront of developing treatments and cures for diseases such as epilepsy and autism. Our mission is to assist investigators with achieving the best imaging research outcomes possible, while also assuring compliance with institutional policies.
The lab performs research in the areas of Bone Marrow Transplantation, Leukemia, Tumor Antigens, and Immunotherapy.
The Rodent Histopathology Core was founded in 1999 as one of the pathology cores within the Dana-Farber/Harvard Cancer Center. The Core was established to provide high quality professional, technical, and educational pathology services. The ultimate goal of the facility has been to support investigator research that leads to the identification of pathologic processes in mice and can be directly translatable to human disease.
The core provides an essential and unique service to the many Center members and labs invested in mouse research. While many commercial and academic histology services are available, no other service is available that offers comparable high quality service with rapid turn around time and highly experienced professional supervision. The educational mission of the Core also adds an important dimension.
Our laboratory focuses on two major areas: 1) understanding the molecular mechanism of insulin and IGF-1 action and their alterations in pathologic states; and 2) the developmental heterogeneity of adipose tissue and its role in diabetes, metabolic syndrome and longevity. To achieve these goals, we use a wide variety of methods ranging from basic cell biology to creation and analysis of tissue-specific knockouts mice, and analysis of human cells and tissues.
The insulin and IGF-1 receptor tyrosine kinases are major regulators of metabolism and growth, and sites of both physiological and disease regulation. Following stimulation, the insulin receptor phosphorylates as many as 10 different intracellular substrate proteins, each of which dock to a number of other intracellular proteins through SH2 and non-SH2 mediated interactions. This results in stimulation of both the PI 3-kinase pathway and the Ras-MAP kinase pathway, as well as activation of many serine and threonine kinases involved in control of metabolism and glucose uptake. To understand the complementarity and redundancy between these various complex pathways, we have utilized cellular transfection models, mouse knockout models and cells derived from knockout mice. We have used this approach to define the differential role of both receptors, their substrates (the IRS proteins) and various components of PI 3-kinase and its downstream target. These studies indicate that the insulin signaling network is a finely tuned network with critical nodes of signal divergence and regulation. Through the use of tissue-specific knockouts created using Cre-lox recombination, the role of each of these pathways in specific insulin actions in specific tissues has been determined. This includes the actions of insulin in both classical targets, like liver, muscle and fat, and non-classical targets, like the brain. We have shown how these genetic modifications are further modulated by acquired alterations and by genetic background in the mouse. We are also studying how these pathways affect longevity and how they are altered in type 2 diabetes, obesity and metabolic syndrome.
The second major focus of the laboratory is defining the developmental origins and heterogeneity of white and brown fat. This is based on the important difference in fat in various depots on development of insulin resistance and energy balance. We have shown that fundamental developmental genes play a role in this process, and that fat cells in different depots have cell autonomous differences in function which affect whole body metabolism. The difference between energy burning brown fat and energy storing white fat also affects metabolism. The role of this heterogeneity and insulin action on mitochondrial function is also being explored at a cellular and molecular level, since mitochondrial function is altered in diabetes and may play an important role in longevity.
The unique ability of stem cells to perpetuate themselves through self-renewal, and to give rise to mature effector cell types in a sustained fashion has positioned stem cell biology at the forefront of regenerative medicine -- the goal of which is to develop strategies capable of harnessing the clinical potential of stem cells to treat both heritable and acquired degenerative conditions. Hematopoietic stem cells (HSCs) are the only cells within the bone marrow that possess the ability to both differentiate to all blood lineages, and to self-renew for life. These properties, along with the remarkable ability of HSCs to engraft conditioned recipients upon intravenous transplantation, have established the clinical paradigm for stem cell use in regenerative medicine. Despite the enormous clinical potential of HSCs, surprisingly little is known about the mechanisms that regulate their fundamental properties of self-renewal and multi-potency. Our lab has a profound interest in understanding the mechanisms enabling self-renewal and multi-potency in HSCs, which we study using cellular, molecular, genetic and epigenetic approaches.
Another focus of the lab is in understanding the extent to which the aging of hematopoietic stem and progenitor cells contributes to the pathophysiological conditions arising in the aged hematopoietic system, which include; declining immuno-competence, diminished stress response, anemia, and cancer. To address this we are evaluating hematopoietic stem and progenitor cells in the context of aging in order to determine the cellular and molecular mechanisms underlying the aging of the hematopoietic system. In particular we are exploring the contribution of epigenetic regulatory mechanisms to hematopoietic stem cell biology and aging. We are also studying the mechanisms through which stem cells maintain genomic integrity, and examining how age-dependent DNA damage accrual impacts stem cell functional capacity to contribute to hematopoietic pathophysiology.
Numerous studies have shown that it is possible to experimentally reprogram the cellular identity of one cell type to another. One approach to effect cellular reprogramming involves enforcing expression of defined transcriptional regulators important for specifying one cell type in a different cell type in order to convert its fate. This methodology is perhaps best exemplified by the generation of induced pluripotent stem (iPS) cells from a variety of differentiated cell types by the ectopic expression of a small number of defined factors. This approach is also proving to be a viable method to reprogram a variety of cell types to alternative fates. Our lab is pursuing several lines of investigation aimed at reprogramming the cellular identity of a number of cell types into clinically useful cell types through various approaches including the use of novel technologies.
The SBGrid Consortium provides structural biologists throughout the world with access to the computing resources they need to discover the shapes of the molecules of life. SBGrid brings together approximately 200 like-minded laboratories all in the business of discovering what biological molecules look like and how they work. The Consortium includes X-ray crystallography, NMR and electron microscopy laboratories worldwide. Members share the costs of SBGrid's support services and gain access to a large collection of scientific applications and extensive computing resources, all maintained at the SBGrid Service Center located in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.
The SBGrid Core team provides research computing sysadmin support to structural biology laboratories in the Boston area.
My lab is investigating the normal cellular functions of signaling pathways implicated in neurological disease, with an emphasis on axon growth and guidance. Our research centers upon the proteins affected in tuberous sclerosis complex (TSC) and spinal muscular atrophy (SMA) -- two neurological disorders whose genetic basis is well understood but whose cell biology remains unknown. As a clinical neurologist, I also treat patients with neurological disease. One of the ultimate goals of our research is to guide the development of therapeutics for disorders of neural connectivity. My team is currently conducting clinical trials investigating new treatments for TSC.
Tuberous sclerosis complex
TSC is a multi-system autosomal dominant disease caused by loss-of-function mutations in the TSC1 or TSC2 gene. This disease is characterized by the formation of benign tumors (hamartomas) in several organs. The brain is almost invariably affected, and patients often present with epilepsy, autism and mental retardation. We hypothesize that a miswiring of neuronal connections may underlie these neurological symptoms.
We have recently found that the Tsc1 and Tsc2 proteins restrict axon formation and growth. In mouse models of TSC, we observe ectopic axons and abnormal axon path-finding in the brain. The axonal functions of the Tsc proteins may be important in understanding the neurological features of the disease--and, more generally, in understanding the pathology of the autism spectrum disorders that affect patients both with and without TSC.
Click to see how TSC proteins control axon development.
We are further exploring the molecular network in which the Tsc proteins function, and have found that modulation of the growth-promoting mTOR pathway, which is regulated by Tsc proteins, can promote axon regeneration in the adult central nervous system. We are also interested in other neuronal functions of the Tsc signaling network, such as the control of neuron size, myelination, survival and stress responses. For instance, my lab, in collaboration with others, has shown that in a mouse model of TSC, neurons are sized abnormally, are not sufficiently myelinated and are prone to cell death. In other studies, we have found that Tsc activity mediates mTOR's response to neuronal stress. In particular, neurons lacking a functional Tsc protein complex are more vulnerable to endoplasmic reticulum stress-induced cell death.
Click to see a schematic of the mTOR signaling pathway.
Spinal muscular atrophy
Our second major line of research aims to understand axonal pathology in SMA, an autosomal recessive neuromuscular disease. SMA is characterized by hypotonia and muscle weakness, as spinal motor neurons are lost, and is caused by mutations in the SMN gene.
It is known that the SMN protein controls RNA processing and is important for axon development, but the details remain enigmatic. We hypothesize that axonal RNA transport and/or translation are not properly regulated in the disease. To investigate this, we are characterizing the role of the SMN protein in axon growth and guidance in vivo, as well as identifying proteins and mRNA targets that interact with SMN in neurons. We hope that our work will provide new insight into the signaling mechanisms responsible for establishing brain circuitry, and ultimately suggest therapeutic interventions for disorders in which these signaling mechanisms are perturbed.
Since my years as a Harvard faculty member, I have focused a sustained effort toward cancer biology, and my initial most significant contribution was the first to discover that pro-survival pathway activation is directly associated with p53-dependent genotoxic responses in cancer cells, and have provided a unique and significant contribution in this area. As an Assistant and then as an Associate Professor at the BIDMC and the MGH/Harvard Medical School, I pursued my major interest in how tumor suppressor p53-mediated transcriptional regulation influences cell fate decisions: live or die. Based on my contribution concerning the dark side of p53 in cancer therapeutics that wt-p53 can function as a guardian of cancer genome for their survival against therapeutic stress, I have established close collaborations with the Broad Institute utilizing their technological, computational and chemical biological tools under their Chemical Genetics Platform. Together with Broad scientists, I have identified several promising small molecules with anti-cancer activity through the activation of tumor suppressor p53 apoptotic pathway. Specifically, we have identified a small molecule to induce apoptosis selectively in cells having a cancer genotype by targeting a non-oncogene co-dependency acquired by the expression of the cancer genotype in response to transformation-induced oxidative stress. This highlights a novel strategy for cancer therapy that preferentially eradicates cancer cells by targeting the ROS stress-response pathway. My experience in this area has played a major role in the development of a Chemical Genetics Core facility at CBRC in collaboration with the Broad Institute. My group now possesses considerable experience in systematic small molecule technologies. I will continue to assist with the design, validation, execution and interpretation of investigator initiated chemical genetic screens.
The Seahorse Core supports the use of an XFe24 Extracellular Flux Analyzer from Seahorse Biosciences to perform sensitive measurements of oxygen consumption rate and extracellular acidification rate in cultured cells, tissues, or model organisms in a 24-well format.
The Molecular Diagnostics Laboratory provides such research services as microRNA expression profiling, human cell line identity verification, mutation detection for clinical research studies, and specimen processing for clinical research studies to investigators at the Dana Farber Cancer Institute, as well as to investigators at other institutions. Consultation on experimental design and assistance with data analysis are also available.
The Sleep & EEG Core within the Division of Sleep Medicine (DSM) provides an integrated infrastructure and knowledge base in support of research projects that use polysomnography (PSG), quantitative EEG analysis and related methodologies. The Core consists of a team of specialists lead by the Core director and a chief PSG technologist.
The Core provides support and services in different areas:
1) It provides basic training and certification in PSG and EEG instrumentation to technicians and investigators, particularly those conducting studies at the Center for Clinical Investigation (CCI) at Brigham and Women’s Hospital.
2) It acts as liaison between DSM investigators and CCI technical staff, and implements and monitors quality assurance measures.
3) It carries out standard vigilance state scoring of PSG recordings and different types of waking EEG and electrooculogram analyses.
4) It carries out spectral analysis of sleep and waking EEG.
5) It evaluates, acquires, and maintains PSG and EEG equipment used by investigators of the CCI.
6) It carries out PSG procedures such as sleep screens and multiple sleep latency tests.
7) It assists investigators in the analysis and interpretation of sleep and EEG data.
Over the years, the Sleep & EEG Core has been a central part of many projects funded by NIH, the Air Force Office of Scientific Research (AFOSR), and the National Space Biomedical Research Institute (NSBRI) that had a main focus on the physiology of human sleep-wake regulation. Scientifically, the Core has contributed by providing investigators with important quantitative measures of homeostatic and circadian components of the human sleep-wake regulatory system.
In recognition of the value of small animal imaging to the research community, Children's Hospital Boston has committed to developing a state-of-the-art Small Animal Imaging Laboratory.
The Small Molecule Mass Spectrometry Facility at the FAS Center for Systems Biology offers support for the analysis of a wide variety of analytes using mass spectrometry based techniques. We are located in the second basement (B2) level of the Northwest Laboratory building at 52 Oxford Street, Cambridge, MA 02138. We provide services for molecular formula confirmation (accurate mass measurement), structural elucidation (MS/MS) and quantitation of small molecules. In addition, we can assist you in the mass analysis of a wide variety of non-proteomics samples including metabolites, medium sized proteins and oligonucleotides. Please contact us and tell us about your samples prior to submission or use of our Open Access laboratory.
Founded in 1971 as the Massachusetts Rehabilitation Hospital, Spaulding Rehabilitation Hospital is one of the largest rehabilitation facilities in the U.S., providing comprehensive rehabilitation treatment.
Tissue analysis is critical to validation and evaluation of animal models of human cancer, and human cancer tissues serve as the "operating system" for translational research. The facility supports a wide spectrum of cancer-relevant research, from basic studies on pathogenic mechanisms in cancer to translational research focused on the development of new tests for biomarkers that stratify patients and direct therapy.
The Specialized Histopathology (SHP) Core has two performance sites: Longwood, Directed by Jon Aster and based at the Brigham and Women’s Hospital and MGH, Directed by Anat Stemmer-Rachamimov and based at Massachusetts General Hospital East in Charlestown.
The SHP Core provides high-quality, timely, state-of-the-art technical and professional pathology services to investigators working in a variety of experimental organisms, including rodents, fish, and monkeys, as well as with human tissues. The Core performs routine histology and special histochemical stains, and also assists in experimental design and the development, application, and interpretation of biomarker tests and their results. Specific services include immunohistochemistry, immunofluorescent staining, and in situ hybridization.
Specialized Histopathology Services- Longwood Core
Brigham and Women's Hospital
75 Frances Street, Thorn 604, 603b
Boston, MA 02115
Specialized Histopathology Services- MGH Core
Massachusetts General Hospital-East
13th Street, Building 149
Charlestown Navy Yard 6, Room 6122
Boston, MA 02129
Stem Book is an open access collection of invited, original, peer-reviewed chapters covering a range of topics related to stem cell biology written by top researchers in the field at the Harvard Stem Cell Institute and worldwide. Stem Book is aimed at stem cell and non-specialist researchers.
In addition to the contributions of the editorial board and the stem cell research community, the project is being done in collaboration with several other enterprises including Harvard’s Initiative in Innovative Computing. The Initiative in Innovative Computing created the Scientific Collaboration Framework (SCF), the extensible software infrastructure used for the project. SCF and the Stem Book project were funded, in part, by a generous grant from an anonymous foundation and also appreciates the input of WormBase's Textpresso team.
The molecular mechanisms of transcriptional regulation are highly conserved among eukaryotes. Transcriptional regulation in response to environmental and developmental cues is mediated by the combinatorial and synergistic action of specific DNA-binding activators and repressors on components of the general transcription machinery and chromatin modifying activities. Much of the work in this laboratory combines genetic, molecular, and genomic approaches available in yeast to address fundamental questions about transcriptional regulatory mechanisms in living cells. In addition, we are defining physiological targets of human transcriptional regulatory proteins and chromatin modifications on a whole-genome basis using a novel microarray approach.
We are interested in structural and evolutionary analysis of genome variation and divergence. We apply bioinformatic approaches to problems of evolutionary genetics and human population genetics.
Additionally we develop novel computational techniques for proteomics and for comparative analysis of protein sequences and structures.
The Surgical Planning Laboratory is advancing the future of health care by bringing the power of computation and imaging to new areas of medicine. The lab collaborates with groups within Brigham and Women's Hospital, with other researchers at the Harvard Medical School, with local universities such as Harvard and MIT, and with gifted clinicians, researchers, and engineers throughout the world. The Core Mission of the SPL is the extraction of medically relevant information from diagnostic imaging data.
This laboratory also has a large publications database.
The Survey and Data Management Core (SDMC) provides efficient, high-quality survey data collection and management services and consultation to support the research needs of investigators and staff throughout the Harvard Medical research community. The Core, housed within the Center for Population Sciences at the Dana-Farber Cancer Institute, is dedicated to rigorous evidence-based quantitative, qualitative and mixed methods data collection and management.
We have many years of experience designing and manufacturing custom tools for medical research. This has allowed us to compile a large collection of different solutions to a wide range of problems. We work on a daily basis with researchers working in these areas of medical science:
- Cell Biology
- Anesthesiology Research
- Surgical Research
- Pathology Research
- Respiratory Biology
- Environmental Sciences
The laboratory studies the genetic basis by which form and structure are regulated during vertebrate development. We combine classical methods of experimental embryology with modern molecular and genetic techniques for regulating gene expression during embryogenesis.
One of the classic systems for the study of embryonic development is the chick embryo, where grafting experiments have given profound insight into such questions as the patterning of developing limb axes, and the control of organogenesis. These classical experiments provide a context for interpreting modern molecular studies and the methods they employed also give us an additional set of tools for manipulating the embryo. For example, we can use retroviral vectors to alter gene expression in the context of specific transplantations or extirpations. Important complementary information is gained from studies taking advantage of the powerful techniques for regulated misexpression and gene deletion in the mouse.
The lab has major efforts underway exploiting these approaches to understand limb development, from the establishment of the initial axes, to understanding the difference in genetic controls between an arm and a leg, through later specific events such as differential bone growth and specific muscle patterning; and to understand the establishment of left-right asymmetry (e.g.. why your heart is on the left and not the right) from the initiation of the left-right difference, through signaling cascades, to left- or right-specific morphogenesis. We also currently have projects looking at patterning of the gut, the differentiation of the somites and morphogenesis of the heart, as well as biochemical analysis of the hedgehog signal transduction system, a key signaling pathway during development.
The Taplin Biological Mass Spectrometry Facility opened in February 2001 as a core facility for the analysis of proteins and peptides by mass spectrometry. The facility is focused on serving the needs of investigators at Harvard Medical School (HMS) and all the Harvard affiliated Institutions.
Technology Transfer at McLean is handled within Research Administration by the Senior Associate Director of Technology Transfer, working as an adjunct to Partners Healthcare Office of Research Ventures and Licensing (RVL). McLean.s Senior Associate Director of Technology Transfer is responsible for the identification and protection of new inventions and other commercially-valuable intellectual property that arises from McLean.s research and clinical activities. The Senior Associate Director also negotiates contracts and other research-related interactions between McLean staff and industry.
McLean investigators are covered by the Intellectual Property Policy for Partners-Affiliated Hospitals and Institutions. The purpose of this Policy is to promote the missions of the Partners Hospitals by making inventions, copyrightable works and other intellectual property that may be created by physicians, researchers, and trainees available for the benefit of the public while also providing for a fair allocation of the financial costs and rewards associated with them.
McLean staff members who believe they have made an invention in the course of their research or clinical practice should contact Research Administration and complete an Invention Disclosure Form. To avoid the possible loss of patent rights in key countries, staff members are strongly encouraged to consult with Research Administration well before publication or public presentation. For those inventions which the Hospital decides to pursue, McLean will seek patent protection and contact potential corporate partners and licensees at McLean.s expense. McLean's Senior Associate Director of Technology Transfer can also answer any questions you may have about patents or the patent process, or can refer you to additional information.
Research Administration should also be consulted before investigators enter into any agreements with pharmaceutical, biotechnology or medical device companies, or other industrial companies. This includes confidentiality agreements, material transfer agreements, consulting agreements, as well as agreements for the industrial sponsorship of clinical or nonclinical research.
As Beth Israel Deaconess Medical Center's (BIDMC) technology transfer organization, the Technology Ventures Office (TVO) serves as a bridge between our medical center's faculty and the business community.
TVO's technically trained and business-oriented professionals work with biomedical companies, venture capitalists, and entrepreneurs to find the best way to transfer BIDMC inventions and innovative knowledge to commercial partners.
The mission of the Technology Ventures Office (TVO) is to promote public utilization of Beth Israel Deaconess Medical Center (BIDMC) technologies for society’s use and benefit, and to foster alliances with industry through collaboration and licensing agreements, while generating unrestricted income to support research at our institution.
We work with biomedical companies, venture capitalists, and entrepreneurs to find the best way to commercialize new technologies and to promote corporate collaborations that can increase our level of industrial support for research.
Boston Children's Hospital's Technology and Innovation Development Office (TIDO) (formerly Intellectual Property Office) is a team of highly motivated professionals with experience in academic and industry biomedical research, technology licensing, company startups, business and law.
Through active partnering with biotechnology, pharmaceutical and medical device companies at all stages (e.g. research, development, pre-clinical and clinical investigation), TIDO works to translate the world-class, cutting edge research conducted at Children's Hospital into new therapies, diagnostics and devices that can benefit the public.
The Tissue Microarray and Imaging Core is dedicated to the construction and evaluation of high-quality tissue microarrays for cancer research. Tissue microarrays enable large-scale, high-throughput in-situ analysis of gene and protein expression. By providing access to this resource, as well as enabling computer-based image analysis, the Core facilitates translational research and the discovery and validation of novel potential drug targets.
The transport, fate, exposure, and toxic effects of heavy metals is a primary focus of research at the Center. The Metals Service provides metals analytical capabilities to biomedical and non-biomedical researchers and serves as a source for study design consultation and sample QA/QC requirements.
The Trace Metals Laboratory operates as a modified fee-for-service laboratory. Researchers have the option of having the samples run by the Service staff, or of receiving instruction (for themselves or a doctoral or post doctoral trainee) on how to operate the analytical equipment and analyze their own samples. Both options have associated fees and, as with other services, facility access funds can be requested internal or external services when individual grant support is not yet available.
The TransLab is an innovative clinical and translational platform that bridges scientific discovery and clinical practice. Our mission is to:
• Provide integrative laboratory services to support clinical trials
• Accelerate the development of novel cell and gene-based therapies
An experienced and qualified professional staff performs the work in a quality-controlled environment. Importantly, the TransLab leverages existing core facilities when needed: flow cores (cell sorting), microscopy core (advanced imaging), genomics cores (sequencing and other assay), biorepository core (long term storage).
The core is supported in part by Boston Children’s Hospital and Dana-Farber Cancer institute. We serve all academic institutions (locally and nationally) as well as biotech and pharmaceutical companies.
The Beth Israel Deaconess Transgenic Core Facility opened in October of 1991.The Transgenic Core is a state-of-art facility that produces genetically altered animals.
The Transgenic Core centralizes the production of genetically altered mice for MRRC investigators in a cost-effective and efficient manner. The Core also provides expert assistance in the additional areas required for generating genetically altered mice, including transgene and targeting construct production, and transgenic mouse colony management. Core personnel are available to train investigators in all of the techniques required for the generation of genetically modified mice.
The Transgenic Mouse Core at Harvard Medical School was established in 1992 operating at the BWH, and is now located at Harvard Medical School and the newest of the DF/HCC cores as of March 2018. The Transgenic Mouse Core provides services for the generation of transgenic and knockout mice using state-of-the-art facilities and equipment.
Dr. Lina Du, formerly a plastic surgeon in Beijing and an expert in microvascular surgery, performs both blastocyst and pronuclear injections. She has over 20 years of experience in embryo manipulation and the generation transgenic mice.
The Transgenic Mouse Core has all of the equipment necessary for generation of transgenic mice including a Nikon Diaphot microscope equipped with Nomarski Optics and Narishige micromanipulators for microinjections, Nikon surgical microscopes for egg isolation ad transfer, a sutter needle puller and a de Fonbrune microforge. The facility maintains mice necessary for egg donors, egg recipients, and vasectomized males. This is a non-profit facility and charges are based upon anticipated mouse costs, maintenance of mice and equipment, purchase of necessary surgical supplies and chemicals, and personnel costs.
ES cell culture services have been offered for 15 years. Our staff carries out electroporation of targeting vectors into ES cells and provides investigators with DNA to identify ES cells carrying the desired recombination events. Staff then expand the appropriate ES cells for microinjection into blastocysts by the Transgenic Mouse Core.
In recent years, the core has expanded its list of services to include CRISPR injections and cryopreservation.
The McLean Hospital Translational Imaging Laboratory aims to provide cutting edge magnetic resonance imaging, functional imaging, chemical imaging (spectroscopy), and multimodal imaging services to the Harvard Catalyst Community. We have 3 magnetic resonance (MR) scanners, an ultra high magnetic field (9.4 Tesla) dedicated animal scanner and 3.0 and 4.0 Tesla large bore human systems available for large animal scans. Our scanners are capable of conducting scans in animals ranging in size from mice to large dogs, and we have experience imaging mice, rats, rabbits, nonhuman primates, and several canine species. All 3 scanners have dedicated animal prep areas. We offer high level biophysics, engineering, and data analytic expertise, along with veterinary technologist anesthesia support.
The Translational MRI Core of the BIDMC Department of Radiology provides state-of-the-art MRI capabilities for imaging human subjects and potentially large animals as part of research studies. The facility operates a research dedicated 3 Tesla system and can provide access to a 1.5 Tesla system. In addition to commercial tools for clinical imaging, customized software and protocols for applications including functional and structural brain imaging, abdominal perfusion and diffusion, muscle functional imaging and spectroscopy are available to users. Additional customization of applications either by the Core staff or in collaboration with the Division of MRI Research is encouraged.
Obesity is an epidemic health problem worldwide, and is a significant risk factor for many human diseases, including diabetes, dyslipidemias, non-alcoholic fatty liver, gallstones, cardiovascular disease, Alzheimer’s disease and even some cancers. Obesity develops when energy intake exceed energy expenditure. Despite this simple nature, the maintenance of energy balance is complex. The long-term research interest in Dr. Tseng’s lab is to understand the regulation of energy homeostasis and use it to develop potential therapeutic approaches for obesity and related diseases. The current research projects in Dr. Tseng’s lab are focused around the following specific areas:
Role of developmental signals in the determination of brown versus white adipose cell fate
Excess adipose tissue is the characteristics of obesity. Two functionally different types of adipose tissues are present in mammals: white adipose tissue, which is the primary site of energy storage, and brown adipose tissue, which is specific to thermogenic energy expenditure. Given its specialized function to dissipate chemical energy, brown adipose tissue provides a natural defense against cold and obesity. Several developmental signaling molecules have been shown to impact development of different adipose depots. These include members of the transforming growth factor β (TGF)-β and bone morphogenetic protein (BMPs) family, the fibroblast growth factor (FGF) family, the wingless (Wnt) family, the hedgehog family and others. Combining cellular, molecular and physiological approaches, Dr. Tseng and her colleagues have discovered that BMP7 specifically promotes brown adipocyte differentiation and function. Treatment of mice with BMP7 results in an increase in brown fat mass and reduced weight gain. Current ongoing studies in Dr. Tseng’s lab are to further determine the role of BMPs in the control of brown versus white adipogenesis and whole body energy metabolism using a variety of in vitro and in vivo approaches. In addition to BMPs, Dr. Tseng and her colleagues continue to identify additional factors that differentially regulate the development and function of brown versus white adipose tissue using genomics, proteomics, and small molecule screenings.
Identification and characterization of progenitor/stem cells that give rise to different adipose depots
The adipose tissue arises from the multipotent stem cells of mesodermal origin. When triggered by appropriate developmental cues, these cells become committed to the adipocytes lineage. It has been suggested that different fat depots located in different anatomical locations of the body may derive from distinct developmental origins. Recently, we have identified and isolated a subpopulation of adipogenic progenitors (Sca-1+/CD45-/Mac1-; referred to as Sca-1+ progenitor cells, ScaPCs) residing in murine brown fat, white fat, and skeletal muscle. ScaPCs derived from different tissues possess unique molecular expression signatures and adipogenic capacities. Importantly, while the ScaPCs from interscapular BAT are constitutively committed brown fat progenitors, Sca-1+ cells from skeletal muscle and subcutaneous white fat are highly inducible to differentiate into brown-like adipocytes upon stimulation with BMP7. ScaPCs from obesity-resistant mice exhibit markedly higher thermogenic capacity compared to cells isolated from obesity-prone mice. Currently, ongoing studies in Dr. Tseng’s lab are to further define these progenitors by single cell analysis, microRNA profiling and in vivo fate mapping.
Integration of central and peripheral controls on whole body energy homeostasis
The maintenance of energy balance involves coordinated changes in energy intake and expenditure, and these two limbs of energy balance are physiologically linked. The central nervous system receives diverse inputs to coordinate appetite and energy expenditure, and is therefore the key control center for body weight. Despite recent advances in defining the neuronal circuits for appetite regulation, factors that regulate feeding via these pathways have not yet been fully elucidated. TGF-β/ BMP are known to regulate neuronal development. Recently, this signaling system has been demonstrated to be involved in the regulation of food intake and energy homeostasis in lower organisms, such as C. elegans and Drosophila. However, whether a similar pathway in the regulation of energy balance exists in mammals is currently unknown. Recently, Dr. Tseng and her colleagues have discovered that in addition to its role in brown adipocyte development, central BMP7 signaling appears to play a critical role in regulation of food intake. Studies in Dr. Tseng’s lab are currently dissecting the molecular and neuronal mechanisms that underlie the anorectic effect of BMP7. Ultimately, we hope this combined knowledge will allow us to integrate central and peripheral controls of energy homeostasis and aid in identifying specific targets for therapy of obesity and diabetes.
Tufts Medical Center is a world-class academic medical center located in Boston. Our Medical Center is the principal teaching hospital for Tufts University School of Medicine. We offer outstanding patient care to both adults and children, teach generations of future physicians the most advanced medical science and break new ground with ongoing, innovative research.
The Tumor Imaging Metrics Core (TIMC), co-Directed by Annick D. Van den Abbeele, MD (DFCI) and Gordon J. Harris, PhD (MGH), is a shared resource that was founded in 2004 to provide standardized, longitudinal tumor metrics for patients enrolled in oncologic clinical trials across the five Harvard teaching hospitals of the DF/HCC. The ordering, communication, workflow, results reporting, electronic signatures, audit trails, criteria conformance, and chargeback billing are all managed through a web-based informatics platform, Precision Imaging Metrics, developed by TIMC, which is currently in use at eight NCI-designated Cancer Centers around the country. Clinical trials imaging assessment results are provided in time for review at the point of care in as little as one hour after completion of scanning. TIMC currently manages over 1,000 active clinical trials and performs over 15,000 image assessments per year for Partners and DF/HCC investigators. The mission of the Tumor Imaging Metrics Core (TIMC) is to provide standardized, consistent, longitudinal radiological measurements to evaluate therapeutic response for DF/HCC clinical trials.
The TIMC -
* Makes reliable, quantitative, longitudinal measurements (such as RECIST, Lugano, irRC, RANO,
standardized uptake value SUV etc.) of lesions from serial MRI, CT, PET, and PET/CT scan images
* Presents results of analyses on a password-protected secure web-based report
* Provides an independent service, with verifiable measurement of treatment response for patients enrolled in cancer center trials
* Serves as a centralized, computerized resource to facilitate efficient internal or external auditing
Ultrasound, which is also known as sonography, is a painless, non-invasive imaging technique that lets us look inside your child's body without the use of radiation. It uses high-frequency sound waves to create pictures of organs, bones, tissues and blood vessels.
Our laboratory focuses on the study of subpopulations of human and murine CD4+ (helper) T cells, which play a central role in the regulation of the immune system. CD4+ T cells have multiple functions, but little is known about mechanisms that selectively activate one function over another. Since the coordinated expression of restricted profiles of lymphokines appears to be the major mechanism for the regulation of these diverse functions, we are examining the cellular, molecular and genetic mechanisms that regulate lymphokine synthesis in CD4+ T cells.
The Vector Development and Production Core provides viral vectors with custom-designed promoters and reporter genes and capacity for gene regulation.
Our research is concerned with structural aspects of protein function. We are interested in how proteins interact with other macromolecules or small-molecule ligands, and how these interactions relate to biological function. In this context, we are interested in identifying small-molecule inhibitors of functionally important protein interactions. To pursue these goals we use NMR spectroscopy, computational methods and chemical biology approaches.
The primary focus of our research is on how protein interactions control gene expression. On the one hand, we want to understand how eukaryotic translation initiation factors regulates the fate of cells. In particular, we are interested in the interaction of the cap-binding protein eIF4E with the mRNA cap, the scaffold protein eIF4G, and the regulatory 4E-BPs, and how these interactions are related to cell transformation and apoptosis. To address this, we have identified small-molecule inhibitors of the eIF4E/eIF4G interaction and found that these may have anti-tumor activity. We are also working on other factors involved in eukaryotic translation initiation, such as eIF2, eIF2B, eIF5B, eIF5 and eIF4A. In a related effort we are interested in the regulation of transcriptional activation. We are studying the interaction of transactivation domains of transcriptional activators with components of co-activator complexes, such as the human ARC or the mediator of yeast.
We also seek to understand mechanisms of T-cell function from structural studies of T-cell protein complexes involving CD2, the αβTCR, CD3, proteins that bind cytoplasmic tails of T-cell receptor proteins, or protein involved in signaling pathways, such as calcineurin and NFAT. In addition, we are interested in protein-protein interactions in apoptosis and inhibitors of pro-survival proteins. This includes studies of several anti- and pro-apoptotic proteins located in the cytoplasm or the mitochondrial membrane.
Furthermore, we are interested in developing improved experimental and computational methods for studying structures of large proteins and protein complexes.
Recently, we have engaged in a project to develop methods for characterizing the health conditions of human individuals from the composition and concentrations of metabolites. Our goal is to develop NMR and mass spectroscopy methods that will allow us to identify individuals with chronic myologenic leukemia (CML) from healthy persons. The methodology being developed has the potential of rapidly monitoring, in a non-invasive way, the status of patients undergoing drug treatment. If successful this approach can be applied for diagnosis and monitoring numerous other diseases.
We are devoted to the study of theoretical population genetics. The goal of population genetics is to identify and to understand the forces that produce and maintain genetic variation in natural populations. These forces include mutation (also recombination and gene conversion), natural selection, various kinds of population structure (e.g. subdivision with migration), and the random fluctuations of gene frequencies through time known as genetic drift. We study these forces mathematically, using both analysis and computation. For more information about specific areas of research, follow the leads to lab members.
Whitehead provides scientists with the resources and freedom to follow their scientific instincts, form novel collaborations and conduct high-risk research. While probing basic biological processes, 16 faculty Members and 2 Fellows develop innovative technologies and lay the foundation for projects that improve human health. They run pioneering programs in cancer research, immunology, developmental biology, stem cell research, regenerative medicine, genetics and genomics—programs with a record of success.
Dr. Woolf’s laboratory is currently devoted to investigating how the functional, chemical and structural plasticity of neurons contributes to adaptive and maladaptive functions of the mammalian nervous system. The group’s major efforts are devoted to the study of pain, the formation of neural circuits during development, and the failure of regeneration in the adult CNS. Most of this work is focused on primary sensory and spinal cord neurons, which are studied using a multidisciplinary approach that spans mouse and human genetics, molecular and cell biology, bioinformatics, synaptic electrophysiology, neuroanatomy, integrative systems biology and behavior. The group works closely with a wide number of academic groups and the pharmaceutical and biotechnology industry to identify and validate molecular targets for novel analgesics and axonal growth determinants. The lab represents a complex mixture of basic and translational neuroscience.
The Wyss Institute for Biologically Inspired Engineering uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world.
Working as an alliance among Harvard's Schools of Medicine, Engineering, and Arts & Sciences, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Children's Hospital Boston, Dana Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, and Boston University, the Institute crosses disciplinary and institutional barriers to engage in high-risk research that leads to transformative technological breakthroughs.
By emulating Nature's principles for self-organizing and self-regulating, Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing. These technologies are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and new start-ups.
The X-ray Crystallography Facility located at 99 Brookline Ave. (Research North) was recently established as a core to serve the needs of investigators in the BIDMC and Harvard Medical School community interested in using structural biology as a tool in their research.
The research in our laboratories are focused on the following three areas:
1. Bioinformatics: The development of high throughput genomic technologies has created many exciting opportunities as well as analysis challenges. Our group has developed some of the most widely used and cited bioinformatics methods to analyze high throughput data. Our transcription factor motif finding tools have been cited over 1500 times and our ChIP-chip/seq peak callers have over 6,000 registered users. We will continue to develop novel computational algorithms to analyze new high throughput data, such as ChIP-seq (MACS, CEAS), RIP-seq, DNase-seq, MNase-seq (NPS), DNA-seq, and RNA-seq (Gfold). We will also build integrative analysis pipelines (Cistrome) to better help experimental biologists, and conduct efficient data integration to better mine the hidden biological insights from publicly available high throughput data and refine hypotheses. Finally, we will integrate good genomics experimental design and bioinformatics analyses to best utilize the newest technologies in gene regulation studies.
2. Epigenetics: Epigenetics play an important role in gene regulation, and include diverse topics such as DNA methylation, nucleosome positioning, histone marks, epigenetic enzymes, and higher order chromatin interactions. We and colleagues generated the first high throughput nucleosome map in the human genome, identified monovalent genes in early embryonic development, and found the relationship between H3K36me3 exon enrichment and co-transcriptional splicing. We will focus on two major areas of epigenetic research. The first is use the dynamics of histone mark ChIP-seq and DNase-seq to infer in vivo transcription factor binding and understand transcription regulatory networks. The second is to use genome-wide approaches to understand the specificity and mechanism of epigenetic enzymes and lncRNAs (with epigenetic function). Despite intensive research efforts, our knowledge about these areas is still limited, so there will be exciting opportunities in the future.
3. Cancer: As one in three people in the developed countries will get cancer, research on the mechanisms and treatments of cancer will become increasingly important. We and colleagues identified the function of estrogen receptor, androgen receptor, and FoxA1 in breast and prostate cancers, TET1 in leukemia, DREAM complex in cell cycle control, and found metabolic and autoimmune genes as signatures associated with cancer initiation. Cancer is a genetic disease amenable for research using genomic approaches. First, we will integrate publicly available high throughput data to better understand cancer pathways. Recently many cancer studies have found mutations or misregulations in epigenetic enzymes. Many pharmaceutical and biotech companies as well as academic scientists are actively developing cancer drugs targeting epigenetic enzymes. We will study the genome-wide function and response of cancer cells to epigenetic drugs, and identify cancer patients that might respond better to certain cancer drugs based on the genetic, epigenetic, and gene expression status of their tumor.
The Young-Pearse lab focuses on the identification of the mechanistic causes of neurodegenerative and developmental disorders of the nervous system, with the ultimate goal of identifying novel targets for therapeutic interventions for these diseases.
We are interested in how kinases in general, and phosphatidylinositol 3-kinases (PI3K) in particular, control malignant transformation. The work of our laboratory integrates molecular biology, tissue engineering and novel mouse models of human cancer to study oncogenic alterations in kinases that are involved in tumor formation and metastasis. In addition to our unique genetically engineered mouse models, we have developed a number of additional experimental systems, including, synthetic human tumors, and kinome-wide libraries of activated kinases to elucidate the mechanisms by which kinases function in cancer.
The PI3K pathway is a key signal transduction system that links oncogenes and multiple receptors to many essential cellular functions, which is tightly regulated by PI3Ks and the tumor suppressor PTEN. This pathway is perhaps the most commonly activated signaling pathway in human cancer, therefore presenting both an opportunity and a challenge for cancer therapy. Studies in our group using genetic engineered mouse models of tissue-specific ablation of PIK3CA or PIK3CB begin to reveal distinct roles of these two isoforms in cellular signaling, metabolism, development and tumorigenesis. For example, PIK3CA plays essential roles in cellular signaling in response to various growth factors, while PIK3CB is important in mediating GPCR signaling. PIK3CA is critical in regulating hepatic and hypothalamic insulin action, glucose homeostasis and energy expenditure. We also made the surprising and important discovery that it is PIK3CB, not PIK3CA, that drives tumor formation in PTEN null prostate tumors. This work provided the foundation for a new field of targeting PI3K isoforms in cancer.
In parallel, we take kinome-wide approaches to the systematic study kinase signaling in oncogenic transformation. We constructed the first kinome-wide libraries of “gain of function” human kinases and used this system in a number of functional genetic screens leading to the identification of novel oncogenes. We also take kinome-wide “loss of function” approaches to decipher the process of transformation. For example, we identified SIK1 as a novel kinase that regulates p53 in response to loss of adhesion. We demonstrated that SIK1 couples LKB1 to p53-dependent anoikis and suppression of metastasis, thus establishing the LKB1-SIK1-p53 axis as a potentially important pathway in metastatic disease.
In summary, our research interests and unique integrated approaches allow us to continue to work at the forefront of cancer biology and foster innovative and productive science.
The laboratory focuses on the developmental biology of hematopoiesis and cancer. We have collected over 30 mutants affecting the hematopoietic system. Some of the mutants represent excellent animal models of human disease. For instance, the isolation of the ferroportin iron transporter was based on a mutant zebrafish and subsequently was shown to be mutated in patients with iron overload disorders. The mutants also represent interesting key regulatory steps in the development of stem cells. We also have undertaken chemical genetic approach to blood development and have found that prostaglandins upregulates blood stem cells. We recently developed suppressor screening genetics and found that transcriptional elongation regulates blood cell fate.
The laboratory has also developed zebrafish models of cancer. A screen for cell cycle mutants found 19 mutants. Some of these mutants get cancer at a very high rate as heterozygotes based on a carcinogenesis assay. We have used small molecules in a chemical suppressor gene to find chemicals that bypass cancer genes. We also have generated a melanoma model in the zebrafish system using transgenics. Transgenic fish get nevi, and in a combination with a p53 mutant fish develop melanomas. We also recently have generated a model of muscle tumors in the zebrafish. This faithfully recapitulates the human muscle tumors and the tumors arise at 10 days of life, making this an ideal system for looking for enhancers and suppressors of cancer.
We study the genetic basis of complex traits and common diseases in humans. Our group is in the Department of Medical Genetics and of Epidemiology of University Medical Center Utrecht, and the Division of Genetics of the Brigham and Women's Hospital and Harvard Medical School. We are also affiliated with the Program in Medical and Population Genetics at the Broad Institute of Harvard and MIT.
A central goal of our lab is to develop computational tools and statistical approaches to analyze patterns of genetic variation in human populations, and to apply these methods to identify genetic determinants of disease susceptibility, disease progression, and drug response.
We pursue these activities in the context of immune-related disorders including HIV/AIDS and autoimmune disease, as well as cerebrovascular and cardiovascular traits, involving many collaborators in Boston and elsewhere.
The Data Collection Core will provide expert services including: study forms design and implementation; training in all aspects of using TELEform software; database construction and exporting / preparing data for statistical applications such as SAS and SPSS; and technical assistance with scanners and computers running electronic form capture process.", "The Research Electronic Data Collection Core can help you capture research data by supporting all aspects of data acquisition, storage and retrieval. The core is designed to significantly improve the efficiency, cost structure and overall quality of research data collection.
Found 368 resource providers .